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Differences of Vascular Remodeling in Human Coronary Artery
Bypass Vessels
Abstract
Koronararterien stellen die Blutversorgung und damit die Funktionsfähigkeit des Herzen sicher. Um
diese auch bei durch atherosklerotische Veränderungen eingeschränktem Blutfluss zu gewährleisten,
werden als Bypass die A. mammaria interna (IMA) oder die V. saphena (SV) genutzt. Der langfristige
Behandlungserfolg ist durch die Bypass Graft Erkrankung limitiert. Im Fall des SV Bypass, aber nicht
des IMA Bypass treten nach 10-12 Jahren entsprechende Veränderungen auf. In dieser Studie konnte ein
prothrombotisches Genexpressionsprofil der SV Gefässe, nicht aber der IMA Gefässe nachgewiesen
werden. Letztere zeigen zudem weitere Eigenschaften, die zum Funktionsverlust des Bypass führen.
Somit liefern diese Daten neue Erklärungen für die unterschiedlich langfristige Funktion von
Bypass-Gefässen.
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1. Abbreviations 
aa: Amino Acid 
CABG:  Coronary Artery Bypass Grafting  
CsA:  Cyclosporine A 
CyPA: Cyclophilin A 
eNOS:  Endothelial Nitric Oxide Synthase  
FX:  Coagulation Factor 10 
FCS:  Fetal Calf Serum 
GTP: Guanine Tri-phosphate 
HAEC:  Human Aortic Endothelial Cells 
IMA:  Internal Mammary Artery 
kDa: Kilo Dalton 
LAL:  Limulus Amoebocyte Lysate 
L-NAME: L-Nitroarginine Methyl Ester (NOS inhibitor) 
LPS:  Lipopolysaccharide 
MAPK: Mitogen Activated Protein Kinase 
MCP-1:  Monocyte Chemoattractant Protein-1 
MMP:  Matrix Metallo Proteinases 
NO: Nitric Oxide 
PAI-1:  Plasminogen Activator Inhibitor-1 
PDGF :  Platelet Derived Growth Factor 
PPIase:  Peptidyl Prolyl cis-trans Isomerase 
PTCA : Percutaneous Transluminal Coronary Angioplasty 
PTEN : Phosphatase and Tensin homolog 
R55A:  PPIase-deficient Cyp A mutant 
SV:  Saphenous Vein 
TF:  Tissue Factor 
TFPI:  Tissue Factor Pathway Inhibitor 
TNF-α:  Tumor Necrosis Factor-α 
THP-1: Monocytic Cell line 
t-PA:  Tissue Plasminogen Activator 
VCAM-1:  Vascular Cell Adhesion Molecule-1 
VSMC:  Vascular Smooth Muscle Cells 
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2. Summary 
Coronary artery bypass graft disease is a form of rapidly progressing 
atherosclerosis that contributes significantly to late morbidity and mortality after 
coronary artery bypass grafting. Arterial (IMA) and venous (SV) grafts are widely 
used to bypass stenosing lesions of coronary arteries. Long term maintenance of 
bypass graft patency is pre-determined by physiological and biological properties of 
the grafts. SV grafts are known to undergo degeneration with a half life of 10-12 years, 
whereas this problem is largely absent in IMA grafts. In this study, we investigated the 
intrinsic cellular and molecular differences between smooth muscle cells of both 
vessels to elucidate intrinsic cellular properties important for bypass graft disease. 
 In acute and subacute stages of bypass graft disease, SV thrombotic events are 
predominant in clinical observations. For this reason, we initially focused on the gene 
expression profile of thrombosis related genes in smooth muscle cells derived from 
these vessels. Microarray analysis revealed 31 genes directly involved in blood 
coagulation, and 2 of these genes were differentially regulated. Interestingly, the pro-
thrombogenic gene tissue factor was upregulated in SV, whereas the fibrinolytic and 
thereby anti-thrombogenic gene tissue plasminogen activator was upregulated in IMA. 
These observations were confirmed at both the RNA and protein level. SV showed 
higher cellular TF protein expression (cytoplasm and membrane bound), which was 
paralleled by a higher activity. In addition, higher TF protein release was observed in 
the culture medium, and factor Xa generation assay for TF activity proved that 
secreted TF was functionally active and co-localized in membrane lipids as micro-
particles. Moreover, SV supernatant exhibited lower levels of the TF antagonist 
protein tissue factor pathway inhibitor (TFPI) and lower levels of the fibrinolytic 
protein t-PA. The supernatant of SV increased clot formation as compared to IMA 
supernatant and control medium. Thus, these data demonstrate that SV has a pro-
thrombogenic gene expression profile as compared to IMA.  
Subacute and chronic stages of coronary atherosclerosis are characterized by 
neointima formation. VSMC migration plays a crucial role in neointima formation and 
atherogenesis. For this reason, we conducted a series of experiments related to these 
VSMC functions. SV exhibited higher migration towards several chemokines (TF-
FVIIa complex and PDGF) and increased stress fiber formation as compared to IMA 
SMC. Rho-ROCK signaling pathway was observed to regulate the PDGF mediated 
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migration and stress fiber formation. The vasoprotective agent endothelial NO is 
known to exert protective effects on vessel homeostasis. For this reason, we studied 
the effect of NO on Rho/ROCK pathway mediated VSMC cell migration. Nitric oxide 
provided to these cells either by overexpression of eNOS gene or added directly 
through an NO donor (DETANO) inhibited SV migration in response to PDGF. 
Further investigations proved that NO inhibited PDGF mediated migration by 
inhibiting the Rho/ROCK signaling pathway.  
In addition to VSMC, monocyte migration also plays an important role in the 
progression of atherosclerotic lesions. VSMC secret a small protein called cyclophilin-
A under stress and inflammatory conditions into the atherosclerotic plaque. Elevated 
levels of cyclophilins are indeed involved in the recruitment of blood monocytes to 
sites of inflammation. We therefore studied the effect of cyclophilin on monocyte 
migration. Our study showed that cyclophilin A is involved in the recruitment of 
monocytes to the vessel. Moreover, a peptidyl prolyl cis-trans isomerase activity 
deficient cyclophilin A mutant (R55A) abolished the migratory effect on these cells. 
These findings demonstrate that secreted cyclophilin A in the atherosclerotic plaque 
can specifically recruit monocytes via its enzymatic activity. 
In summary, this work identified primary intrinsic differences in human SMC 
from IMA and SV. Although the experiments were performed in vitro, the data were 
obtained using human material; hence, the functional differences observed may be 
relevant for bypass graft disease. Indeed, these observations may provide a better 
understanding of both early (thrombosis and occlusion) and late stages (neointima 
formation and atherogenesis) of the disease process.  
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3. Zusammenfassung  
Koronare Bypassgefässe sind häufig von einer Form der progressiven 
Atherosklerose betroffen, die entscheidend zur Morbidität und Mortalität nach 
koronarer Bypass-Operation beiträgt. Um stenosierte Läsionen der Koronararterien zu 
überbrücken, kommen sowohl arterielle (Arteria mammaria interna IMA) als auch 
venöse (Vena saphena SV) Gefässe zum Einsatz. 
Unterschiede in der Funktionalität ergeben sich auf lange Sicht aus den 
unterschiedlichen physiologischen und biologischen Eigenschaften des Bypassgefässe. 
Es ist bekannt, dass SV Gefässe im Gegensatz zu IMA Gefässen, die auch nach langer 
Zeit keine Degenerationen aufweisen, ihre Funktion nur etwa 10-12 Jahre erfüllen 
können. In dieser Studie wurden die zellulären und molekularen Unterschiede von 
glatten Muskelzellen der oben beschriebenen Gefässtypen untersucht. Hierbei war das 
Ziel, wichtige zelluläre Eigenschaften aufzudecken, die zur Entstehung der Bypass 
Graft Erkrankung beitragen.  
Im akuten sowie subakuten Stadium bestimmen thrombotische Ereignisse das 
klinische Bild. Aus diesem Grund wurde als erstes ein Genexpressionsprofil 
Thrombose- assozierter Gene von glatten Muskelzellen der SV und IMA erstellt. Die 
Microarray-Analyse zeigte, dass 31 Gene direkt an der Blutgerinnung beteiligt sind, 
wobei zwei davon gefässpezifisch unterschiedlich reguliert waren. In der Tat war das 
Gen für den prothrombotischen Tissue Factor in SV-Gefässen hochreguliert und das 
Gen, das für den fibrinolytischen beziehungsweise antithrombotischen Geweb 
Plasminogen Aktivator kodiert, in SV-Gefässen herunterreguliert.  Diese 
Beobachtungen wurden sowohl auf der RNA- als auch auf der Protein-Ebene bestätigt.  
SV-Gefässe zeigten eine höhere Expression von zellulärem TF Protein (zytoplasma- 
und membrangebunden), die auch mit einer höheren TF-Aktivität einherging. Zudem 
wurde im Kulturmedium eine gesteigerte TF-Sekretion beobachtet. Ein Test für die 
Aktivität von TF, der auf dem Nachweis der Bildung von Faktor Xa beruht, zeigte 
eindeutig, dass es sich bei dem gebildeten TF um funktionell aktives Protein handelte, 
welches sich in Membranlipidschichten als Mikropartikel einlagerte. Darüber hinaus 
waren im SV-Überstand der Zell-Kultur geringere Konzentrationen des TF 
Antagonisten tissue factor pathway inhibitor (TFPI) und des fibrinolytischen Proteins 
t-PA nachzuweisen.  Der SV-Überstand verstärkte entsprechend, verglichen mit dem 
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IMA-Überstand, die Gerinnung. Zusammengenommen demonstrieren diese Daten, 
dass SV verglichen mit IMA ein prothrombotisches Gen-Expressionsprofil aufweist.  
Das subakute und chronische Stadium ist durch die Bildung einer Neointima in 
den Bypassgefässen charakterisiert. Hierbei ist die Migration von VSMC ein 
Schlüsselereignis, was ebenso für die Atherogenese gilt. Aus diesem Grund wurden im 
Rahmen unserer Untersuchungen eine Reihe von Experimente durchgeführt, die mit 
der VSMC Funktion im Zusammenhang stehen. SV SMC zeigten im Vergleich zu 
IMA SMC eine höhere Migration, die durch verschiedene Zytokine (TF-FVIIa and 
PDGF) ausgelöst wurde, sowie eine ausgeprägtere Bildung von Stressfasern. Es 
konnte auch beobachtet werden, dass der Rho/ROCK Signaltransduktionsweg die 
PDGF-vermittelte Migration und auch die Bildung von Stressfasern reguliert. Da 
bekannt ist, dass endotheliales NO einen protektiven Effekt auf die Gefässhomöostase 
ausübt, wurde der Einfluss von NO auf die Rho/ROCK vermittelte Migration von 
VSMC untersucht. NO wurde diesen Zellen entweder durch eNOS Überexpression 
oder direkt über einen NO-Donor (DETANO) zugeführt, wodurch es zu einer 
deutlichen Verringerung der durch PDGF induzierten Migration kam. Darauffolgende 
Untersuchungen bewiesen, dass NO die PDGF vermittelte SMC Migration über eine 
Hemmung des Rho/ROCK Signaltransduktionsweges deutlich verringert.  
Zusätzlich zu den VSMC ist auch die Monozyten Migration für die Progression 
der Atherosklerose von entscheidender Bedeutung. VSMC sezernieren unter Stress 
oder durch entzündliche Prozesse ein Protein namens Cyclophilin A. Erhöhte 
Konzentrationen von Cyclophilin A sind unter anderem für den Übertritt von 
Monozyten aus dem Blut in die atherosklerotische Gefässwand mit verantwortlich. 
Eine Peptidyl-prolyl-cis-trans-isomerase defiziente Mutante (R55A) des Proteins wies 
keinen Einfluss auf die Migration dieser Zellen mehr auf. Dies zeigt, dass Cyclophilin 
A in der atherosklerotischen Plaque via seine enzymatische Aktivität spezifisch 
Monozyten zum Eindringen in die Gefässwand rekrutieren kann. 
Zusammengefasst zeigt die Arbeit intrinsische Unterschiede zwischen 
menschlichen Muskelzellen von IMA und SV.  Dabei ist wichtig hervorzuheben, dass 
die Daten aus menschlichem Material erstellt wurden, sodass die durch in vitro 
durchgeführten Experimente aufgezeigten funktionellen Unterschiede durchaus für die 
Pathogenese der Bypass-Graft-Erkrankung relevant sein könnten. Insbesondere 
können diese Daten ein besseres Verständnis der frühen (Thrombose und Okklusion) 
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wie auch der späten (Neointima Bildung und Atherogenese) Stadien dieser Erkrankung 
vermitteln. 
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4. Introduction 
4.1. Inflammation 
Inflammation is a complex response of vascular tissue to harmful stimuli. It is 
an initial protective effort by the immune system to remove the injurious stimuli and 
initiates the healing process. However, chronic inflammation may cause several 
disorders (e.g. atherosclerosis and rheumatoid arthritis). Elevated inflammatory 
response in atherosclerotic plaque development is one of the main reasons of coronary 
heart disease 1-3 which results in atherosclerosis lesions and poor blood flow to the 
underlying tissue.  
The atherosclerosis disease process is initiated by inflammation with the initial 
response to the damaging stimuli (e.g. oxidized LDL) by increased movement of blood 
leukocytes into the injured tissue. A cascade of events propagates the inflammatory 
response, involving both the local vascular system (e.g. endothelial cells and VSMC 
etc.) and the immune system (e.g. lymphocytes and monocytes etc.). Prolonged 
inflammation (chronic form) leads to progressive changes in the phenotype of cells 
(e.g. monocytes to macrophages) and secretes substances that stimulate other cell 
populations to produce additional factors and matrix degrading enzymes. Thereby, the 
plaques progress and finally become unstable. 
 
4.2 Coronary artery disease 
 General aspects 
The heart is a pressure generating organ; its active muscle action pumps 
approximately 7200 liter/day of oxygenated blood under normal physiological 
conditions. To perform such a dynamic function, the heart muscle (myocardium) must  
 
 
Figure 1: The three layers of a blood vessel: (A), tunica intima (endothelium); (B), tunica media 
(smooth muscle cells); (C), tunica externa (fibroblasts). Picture is not drawn to the scale. 
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receive large amounts (250 ml per minute or 5% of cardiac output) of oxygenated 
blood through the coronary arteries. Vascular structure is differentiated into three basic 
layers, namely the intima, media, and adventia (Figure 1). Thickening of the vessel 
wall with accumulation of oxidized LDL and infiltrated blood cells in sub-intimal 
layer initiates neointima formation. Further, progression of neointima to atheromatous 
(soft) plaque formation with a characteristic of necrotic core leads to the development 
of advanced lesions. Atherosclerosis of coronary arteries (Figure 2) leads to poor 
supply of blood to the myocardium. Additionally, plaque rupture resulting from 
inflammatory alterations initiates thrombotic (blood clotting) events resulting in 
myocardial infarction (macroscopic area of necrotic tissue) and heart failure.   
 
Atherosclerosis belongs to the chronic inflammatory diseases. It begins as a 
response to risk factors such as hypercholesteremia, diabetes mellitus, hypertension, 
hyperhomocystemia, and smoking 4. Exposure of the endothelium (innermost layer, 
Figure 1) to the blood born inflammatory substances initiates adhesion molecule 
expression and proceeds with dysfunction 5-8. Among other adhesion molecules, 
VCAM-1 expression on the endothelium is crucial for blood cell attachment and 
migration 9. 
Monocytes migrate through the endothelium and differentiate into macrophage 
phenotype which is susceptible for lipid loading. The fate of macrophages residing in 
the vessel wall depends on several inflammatory mediators in the plaque (Figure 3). In 
addition, macrophages release a variety of cytokines, chemoattractants, and matrix 
metalloproteinases. These factors activate surrounding vascular cells (e.g. smooth 
muscle cells and fibroblasts) for further development of chronic inflammatory 
 
Figure 2: Occlusive coronary atherosclerosis. The artery at the left is narrowed by 60 to 70%. The 
artery at the right is with the organization of a thrombus and recanalization such that there are three 
small lumens remaining, one of which contains additional recent thrombus. 
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situation. Continuous cycling of inflammatory and necrotic responses from both 
macrophages and vascular cells turns the atherosclerotic plaque into an unstable form. 
Vulnerability of plaque renders the vessel susceptible to plaque rupture, occlusion, and 
halted blood flow (Figure 2) 4, 9. 
 
 
Figure 3: Schematic representation of steps involved in atherosclerosis and inflammation process. 
Rolling, adhesion and migration of leukocytes into the vessel precedes with the activation macrophages 
and foam cell formation. Foam cells secrete pro-inflammatory cytokines resulting in aggravation of the 
inflammation. (Adapted from Peter Libby, NATURE, VOL 420, 19/26 DECEMBER 2002 ) 
 
 Nitric Oxide: 
NO is an important signaling molecule that contributes to several physiological 
and pathological processes. An optimal level of NO production in the body is 
necessary for the protection from ischemic damage of the organs. NO is predominantly 
produced by vascular endothelium with the help of eNOS enzyme. NO produced from 
L-arginine via endothelial nitric oxide synthase (eNOS) is a potent vasodilator, platelet 
inhibitor, and reduces SMC proliferation and migration 10, 11. NO can affect proteins 
involved in cell cycle regulation and in turn induce cell cycle arrest 12-14.  
SMC are involved in vascular remodeling and the development of vascular 
diseases such as atherosclerosis, restenosis, and bypass graft disease 15-17. A variety of 
released  factors such as PDGF, bFGF, and thrombin modulate the vascular 
remodeling process by regulating proliferation and migration of SMC 18-20. In addition, 
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structural proteins such as degraded matrix proteins in the vessel wall are also involved 
in SMC migration 21. Generally, migration of cells is regulated by several signal 
transduction pathways such as p44/p42mapk, p70S6K, and Rho GTPases upon 
stimulation 22-24. Receptors on the cell surface transmit the extracellular signals into the 
cell nucleus via a variety of signaling cascades, thereby activating transcription factors 
and regulating gene expression and cellular responses. Rho GTPases belong to a novel 
subgroup of the Ras superfamily of 20- to 30-kDa GTP-binding proteins. They 
function as molecular switches, cycling between an inactive GDP-bound state and an 
active GTP-bound state. These proteins exhibit regulatory functions belonging to cell 
proliferation and migration 24. However, it is still unclear through which signal 
transduction pathways NO regulates VSMC migration. Therefore, NO mediated 
inhibition of intracellular signal transduction pathways of cell migration in VSMC on 
Rho A pathway was addressed. 
 
 Cyclophilins: 
Cyclophilins belong to the immunophilin family of proteins found in the 
cytoplasmic portion of the cell. These proteins possess cis-trans isomerase activity 
which aids in proper folding of denatured proteins under stress conditions 25. 
Immunophilins are divided into cyclophilins, FKBPs, parvulins and pin1 families 
based on their functional differences. Cyclophilins and FKBPs bind to 
immunosuppressive drugs such as cyclosporine and FK506. The cyclophilins are 
divided into small (18kDa) and large cyclophilins (40kDa) based on their molecular 
weight. Cyclophilin A belongs to the small cyclophilin family and is found 
ubiquitously in different cell types 26. 
Intracellular cyclophilins are involved in the molecular chaperon function, whereas 
extracellular cyclophilins are released upon stress conditions functioning as a cytokine 
and growth factor 27,28. Moreover, extracellular cyclophilins are shown to be involved 
in the regulation of inflammatory response via the membrane receptor CD147 in 
different cell types 29, 30.  Interestingly, elevated levels of extracellular cyclophilins 
were identified in the necrotic core region of atherosclerotic plaques 31. Hence, the role 
of extracellular cyclophilin A in atherosclerosis disease development was investigated 
in vascular cells. 
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4.3 Therapy for coronary artery disease 
Atherosclerosis and superimposed thrombosis in coronary artery disease 
(Figure 2) can lead to a reduction in blood flow and oxygen supply to the myocardium. 
Significant reduction in the blood flow in patients induces myocardial infarction and 
should undergo interventional or surgical treatment. Therapy for the coronary 
complications is basically divided into two types.  
 
 Intervention (PTCA): 
Common interventional procedures to treat coronary artery disease include 
balloon angioplasty (PTCA) and stent or drug-eluting stent placement. These 
procedures are considered non-surgical because they are done by a cardiologist with 
the help of a tube or catheter inserted into a blood vessel, rather than by a surgeon 
through an incision. Several types of balloons and/or catheters are available to treat the 
plaque within the vessel wall. The physician chooses the type of procedure based on 
individual patient needs. In addition, a stent can be inserted into a natural conduit of 
the body to prevent or counteract a disease-induced localized flow constriction during 
the PTCA procedure (Figure 4). 
 
 
 
Figure 4: Percutaneous transluminal coronary angioplasty: 1-Insertion of catheter; 2-Inflation of the 
balloon; 3- Reshaping of vessel (Adapted from MAIN-TAUNUS PVT CLINIC) 
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 Surgery (CABG): 
 One or more blocked coronary arteries are bypassed by an autologous (same 
patient) vessel graft to restore normal blood flow. These grafts usually come from the 
patient's own arteries and veins located in the chest (Internal mammary artery), leg 
(saphenous vein), or arm (radial artery). These bypass grafts are implanted so as to 
bridge the clogged artery (or arteries) to create a new pathway (a bypass) for 
oxygenated blood flow to the heart (Figure 5).    
 
These procedures principally restore blood supply to the infarcted area, but are 
not a permanent cure for coronary heart disease. Careful attention has to be taken to 
reduce the risk factor prevalence for future disease progression. 
 
4.4. Coronary Artery Bypass Graft Diseases 
 General aspects 
Among all grafts used for revascularization, IMA and SV are widely accepted 
based on their patency and availability 32.  Comparison study of  these grafts in CAD 
patients, revealed that IMA graft possessed a better patency over SV grafts (Figure 6) 
33. Within 4 weeks after grafting, veins showed thrombotic events and intimal 
hyperplasia (SMC proliferation), progressing towards fibrotic intima formation in one 
year and advanced atherosclerosis in three years 34.  
 
Figure 5: Schematic representation of coronary artery bypass surgery. Left panel indicates the 
narrowing of the artery (inset) at two sites. Right panel represent the revascularization procedure after 
bypass surgery. Saphenous vein (SV/ blue) and internal mammary artery (IMA/ red) are used for 
revascularization. (Adapted from www.nucleusinc.com) 
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Under physiological conditions both veins and arteries possess a distinct vessel 
composition. Veins exhibit high levels of collagen content to resist the higher wall 
tension while acting as a reservoir, whereas arteries contain more elastin fibers for 
efficient stretching in response to pulsatile blood flow and vaso-reactive substances. 
Moreover, arteries contain a thicker muscle layer compared to veins (Boron & 
Boulpaep, Medical Physiology, Chapter-18.6) which contributes to the differences in 
vessel deformation and transmural pressure in veins and arteries (Figure 7). 
 
 Fig 6 
 
Adapted from  Loop F.D. et al. N Engl J Med 
1986;314:1-6  
 
 
Figure 7: Differences in transmural pressure and deformation capabilities in a vein (Blue) and an artery 
(red). Vena cava exhibits more elastin and aorta contains more collagen which is important for 
performing different physiological functions upon exposure to different blood pressures. (Adapted from 
Boron& Boulpaep, Human Physiology) 
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  Vascular smooth muscle cells and patency 
The vertebrate circulatory system is composed of arteries and veins. The 
functional and pathological differences between these vessels reflect their 
physiological functions such as oxygenation, blood pressure, and wall tension 35.  
Among all cell types of the vasculature, SMC possess heterogeneity from 
diverse vascular beds and in different developmental stages 36-38.  Both veins and 
arteries originate from mesenchyme (stromal connective tissue) during the embryonic 
development. SMC isolated from veins and arteries share several common features, 
including similar morphology, responses to mitogens and chemoattractants 37-39. 
Despite the same embryonic origin, these vessels possess differences in hemodynamic 
resistance and physiological functions. Generally, arteries (e.g. coronary arteries) are 
more prone to atherosclerosis compared to veins under normal anatomic conditions, 
despite the exposure to common systemic risk factors such as smoking, 
hyperlipidemia, and hyperglycemia. In contrast, after implantation in the arterial 
system as a bypass graft, saphenous veins become highly vulnerable to accelerated 
atherosclerosis 40. Importantly, despite of being an artery, IMA is resistant to both 
atherosclerosis and bypass graft disease. An other conduit used for bypass surgery, the 
radial artery showed lower patency upon grafting 41, 42. Both SV and RA possessed 
similar properties in SMC proliferation and migration. These characters select IMA as 
a successful graft for treating coronary artery disease. Comparison studies showed that 
SMC from SV and RA exhibited different functional properties and undergo extensive 
vascular remodeling as compared to IMA after grafting 42, 43.  
Vascular SMC and infiltrating leukocytes show a unique role in many disease 
processes such as atherosclerosis, bypass graft disease, and post angioplasty restenosis 
9, 44. After CABG, approximately 50% of the SV grafts are occluded in a 10 year 
period due to intimal hyperplasia and accelerated atherosclerosis 45. VSMC 
proliferation, migration, and thrombotic events can be induced by several cytokines, 
growth factors, modified lipoproteins, and matrix metalloproteinases, and this response 
with time turns the vessel susceptible to atherosclerosis.  Higher proliferation rates of 
these cells have been demonstrated leading to the narrowing of the lumen and are 
involved in key steps of neointima formation and atherosclerosis development 46, 47. 
Consistent with an accelerated atherosclerosis, SMC from SV possessed higher 
proliferation rates in response to FCS, PDGF, and MCP-1, which were connected to 
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differential activation and expression of MAPK, receptors and cell cycle proteins 37, 
38,48.  
Clinical observations with respect to the vascular remodeling process 
especially in SMC from diabetic patients possessed higher migration, adhesion, and 
proliferation 49.  Treatment strategies on inhibition of SMC proliferation and activation 
exhibited increased graft patency in CABG by modulating the vascular remodeling 
process. Statin therapy, over expression of signaling molecules such as PTEN, and 
wild type p53  treatments in SV SMC indeed resulted in decreased intimal hyperplasia 
and increased apoptosis 50, 51,52.  
 
 Tissue Factor and patency 
TF is a membrane bound glycoprotein, serves as receptor for FVIIa, and initiates 
coagulation. It is comprises of 263 aa with a 219 aa extracellular domain, 23 aa  
 
transmembrane domain and 21 aa cytoplasmic domain. Plaque disruption with 
superimposed thrombosis is the main cause of acute coronary events such as 
myocardial infarction and unstable angina. Among several agents, TF plays an 
important role in determining the plaque thrombogenicity. TF is not only a potent 
initiator of the coagulation cascade (Figure 7), but also influences the adhesion and 
trafficking of monocytes into the vessel through the endothelium 53. Interestingly, mice 
expressing low amounts of TF were shown to have reduced intimal hyperplasia in 
response to injury and reduced smooth muscle migration 54. Different agonists are 
 
Figure 8: Schematic representation of extrinsic blood coagulation initiated by the complex of tissue factor/ 
factor VIIa complex. Tissue factor pathway inhibitor (TFPI) and tPA mediated inhibition of cascade was 
showed in red lines. 
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involved in the process of atherosclerotic plaque formation and tissue factor expression 
in monocytes, macrophages, and endothelial cells 55 which demonstrates the 
importance of this protein in the inflammation process. 
TF is synthesized at the subendothelial level by SMC in the tunica media 
(Figure 1) and predominantly by fibroblasts in the adventitia surrounding the vessels 
56, 57
. The presence of TF is anatomically separated from the blood born components, 
which however, can be contacted upon vessel injury or plaque rupture. Endothelial 
cells and leukocytes does not express TF under normal physiological conditions, 
however, in response to a variety of stimuli, TF expression is induced in different cell-
types and it has been the subject for many research studies 58-63. Approximately 20% of 
TF is present on the surface of the SMC, and the remaining TF is considered to be 
localized either on the surface, as an encrypted form, or in the cytoplasmic pool 64. 
Hence, disruption of the endothelial layer exposes vascular matrix and SMC TF to 
circulating coagulation components leading to clot formation.  
Clinical observations demonstrate that monocytes from patients with unstable 
angina showed a higher TF like procoagulant activity in-vitro than control subjects or 
patients with stable angina 65. A higher monocyte TF-like activity was shown in 
patients who had recently suffered an acute myocardial infarction compared to healthy 
controls66. Unstable angina patients exhibit higher levels of TF expression both in 
unstimulated and endotoxin-stimulated monocytes, compared to patients with stable 
angina and acute myocardial infarction 67 (Figure 8).  Increased monocyte TF 
expression is seen in patients with an acute coronary syndrome and less pronounced, in 
patients with chronic stable angina 68. Recognizing the TF as a key mediator of 
inflammation and coagulation in coronary artery diseases, several treatment strategies 
were developed a variety of inhibitors were implemented such as recombinant TFPI, 
tPA, uPA, active site inactivated FVIIa proteins (FVIIai) and therapeutic antibodies 
targeting the coagulation factors 69-75.      
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 To address the role of SMC in graft patency and to identify the functional 
relevance in vascular vessel remodeling, we have isolated SMC from the IMA and SV 
(Figure 8) and microarray technology was applied to understand the intrinsic 
differences between these two vessels.   
 
 
Figure 8: Smooth muscle cells from internal mammary artery (red) and saphenous vein (blue) were 
isolated with explant method and affymatrix microarry analysis of genes was performed in 9 patients. 
IMA and SV from single patient were paired for comparison. SMC proliferation differences can be 
observed between IMA and SV in a single explant. 
Isolation of 
VSMCs SV 
MA 
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5. Results and Contribution 
 
5.1. Prothrombotic Gene Expression Profile in Vascular Smooth Muscle Cells of 
human Saphenous Vein, but Not Internal Mammary Artery (23-29) 
Generated all the experimental results except the isolation of RNA and statistical 
analysis of Micro array results in collaboration with Functional Genomic Center 
Zurich, University of Zurich, Switzerland. 
 
5.2. Different migration of vascular smooth muscle cells from human coronary 
artery bypass vessels. Role of Rho/ROCK pathway (30-37) 
Generated rescue experiment (Figure 3) for the revision. 
 
5.3. Endothelial nitric oxide synthase gene transfer inhibits human smooth muscle 
cell migration via inhibition of Rho/ROCK pathway (38-43) 
Performed all the revision work (Migration experiments, NO measurements and 
Cytotoxic assays) 
 
5.4. Cyclophilin A differentially activates monocytes and endothelial cells. Role of 
purity, activity, and endotoxin contamination in commercial preparations 
(44-51) 
Performed all experiment except the PPIase assay in collaboration with Max-
Planck Research Unit for Enzymology of Protein Folding, Halle an der saale, 
Germany. 
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Prothrombotic Gene Expression Profile in Vascular Smooth
Muscle Cells of Human Saphenous Vein, but Not
Internal Mammary Artery
S.K. Payeli, R. Latini, C. Gebhard, A. Patrignani, U. Wagner, T.F. Lu¨scher, F.C. Tanner
Background—The resistance of internal mammary artery (IMA) toward thrombotic occlusion and accelerated atheroscle-
rosis is not well understood. This study analyzed gene expression profiles of vascular smooth muscle cells (VSMCs)
from IMA versus saphenous vein (SV).
Methods and Results—54675 probe sets were examined by Affymetrix microarrays. Thirty-one genes belonged to the
coagulation system; 2 were differentially expressed, namely tissue factor (TF) and tissue-type plasminogen activator
(tPA). TF was 3.1-fold lower in IMA than SV (P0.006), whereas tPA was 9.0-fold higher (P0.001). TF mRNA
expression was lower in IMA than SV (P0.05); tPA was higher (P0.001). TF protein expression was 4.20.5-fold
lower in IMA than SV (P0.001); tPA was 2.60.4-fold higher (P0.01). In IMA VSMC supernatant, TF protein and
activity was lower (P0.05), TFPI and tPA protein higher (P0.05 and P0.005), and clotting time of human plasma
prolonged (P0.05) as compared to SV. Migration to TF/FVIIa (109 mol/L) was 3-fold lower in IMA than SV
(P0.01); PAR-2 protein expression was similar (PNS), PAR-2 blockade without effect (PNS).
Conclusions—Among the genes of the coagulation system, TF and tPA are differentially expressed in VSMCs from IMA
versus SV. This is consistent with protection of IMA from thrombus formation and vascular remodeling. (Arterioscler
Thromb Vasc Biol. 2008;28:705-710)
Key Words: bypass graft disease  tissue factor  tissue plasminogen activator  coagulation  migration
Coronary artery bypass grafting improves prognosis ofpatients with coronary artery disease.1,2 Various factors
predict graft patency, such as the surgical technique, cardiovas-
cular risk factors, and low left ventricular ejection fraction.3,4 In
addition, the type of graft has a major influence on survival;
indeed, patients with 2- or 3-vessel disease receiving an internal
mammary artery (IMA) in addition to saphenous vein (SV)
grafts exhibit higher long-term survival rates as compared to
patients treated with veins only.1,2 This difference is related to
the occurrence of SV graft disease, an adaptive response of
venous grafts leading to accelerated atherosclerosis, whereas the
IMA is strikingly resistant toward such alterations.5
SV graft disease is determined by thrombosis, intimal hyper-
plasia, and accelerated atherosclerosis.6 Thrombosis is the main
cause for vein graft occlusion within the first months after
bypass surgery, whereas the neointimal changes prevail at later
stages. Even when conducted under optimized conditions, har-
vesting of SV grafts causes extensive endothelial disruption;
indeed, more than 50% of the endothelial layer is denuded after
preparation.7 Loss of the endothelium activates coagulation via
the exposure of tissue factor (TF), a key protease activator
forming a catalytic complex with factor VIIa and thereby
initiating coagulation, on vascular smooth muscle cells
(VSMCs).8 The important role of TF in the hemostatic activation
phase early after bypass surgery is underscored by the observa-
tion that expression of TF is enhanced after coronary artery
bypass grafting irrespective of whether an on-pump or off-pump
procedure was performed.9 To limit thrombus formation, vascu-
lar cells express fibrinolytic proteins such as tissue plasminogen
activator (tPA), an enzyme mediating the conversion of plas-
minogen to plasmin. The endothelium is indeed a rich source of
tPA; loss of the endothelial layer renders fibrinolysis dependent
on tPA released from VSMCs.10
In the pathogenesis of bypass graft disease, thrombosis is
interlinked with the development of intimal hyperplasia and
accelerated atherosclerosis. VSMCs indeed migrate and pro-
liferate in response to both coagulation factors and platelet-
derived mediators.11,12 TF/FVIIa is known to stimulate mi-
gration of VSMCs; accordingly, mice lacking the cytoplasmic
domain of TF exhibit reduced neointima formation and
vascular remodeling after femoral artery injury.13 Hence,
mediators primarily regulating thrombus formation in bypass
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grafts may affect the development of later stages of bypass
graft disease as well.
VSMCs are a heterogenous cell population, and different
intrinsic properties of VSMCs from IMA versus SV seem to
represent an important factor in the pathogenesis of bypass graft
disease. VSMCs from IMA indeed exhibit lower contractility as
well as lower proliferation and migration rates compared to cells
from SV.5,12,14 To improve our understanding of this heteroge-
neity, we compared the expression profile of genes involved in
coagulation between VSMCs from IMA and SV segments
retrieved during coronary artery bypass surgery using the Af-
fymetrix microarray technology.
Materials and Methods
For the detailed Materials and Methods please see online supplement
Materials and Methods at http://atvb.ahajournals.org.
VSMCs of IMA and SV were isolated from 9 patients undergoing
coronary artery bypass grafting. VSMCs were cultured as described14
and only compared if they originated from the same patient.
RNA was isolated using TRIZOL reagent. 15 g of biotin-labeled
cRNA samples were randomly fragmented at 94°C and hybridized to
human genome U133 Plus 2.0 arrays. An Affymetrix gene chip
scanner 3000 was used to measure fluorescent intensity. Values were
always represented with respect to IMA VSMCs. Only genes
exhibiting a more than 2-fold difference in expression were included
for further analysis.
Real-time polymerase chain reaction (PCR) was applied to con-
firm microarray data as described.15 Protein expression was deter-
mined by Western blot analysis as described15; alternatively, ELISA
was used. The effect of VSMC supernatant on clotting time was
determined using a Start fibrometer after initiating coagulation by
the addition of 50 L calcium chloride. VSMC migration in response
to TF/FVIIa complex was assessed in a 48-well modified Boyden
chamber (Neuroprobe) as described.12
Results
Eight Genes Related to Blood Coagulation Are
Differentially Expressed in VSMCs
From IMA and SV
Gene expression profiles of VSMCs from IMA and SV seg-
ments obtained from 9 patients during coronary artery bypass
surgery were assessed by Affymetrix human genome U133 Plus
2.0 arrays (54675 probe sets). According to the Affymetrix
database, 247 genes are related to blood coagulation; the relative
expression levels of these genes are indicated along with the
respective probability values (n9) in the online supplement
“Gene List” at http://atvb.ahajournals.org. Among the 247
genes, 8 genes (11 probe sets) were differentially expressed in
VSMCs from IMA versus SV as defined by a more than
2-fold difference in expression level and statistical signifi-
cance (P0.05) in the online supplement Figure at
http://atvb.ahajournals.org.
Two Genes Belonging to the Coagulation System
Are Differentially Expressed in VSMCs
From IMA and SV
The 247 genes related to blood coagulation were filtered by the
Kyoto Encyclopedia of Genes and Genomes (KEGG; University
of Tokyo) pathway database. This analysis indicated 31 genes
belonging to the coagulation system (Figure 1). The gene
expression profile of these 31 genes was compared between
VSMCs from IMA and SV, which revealed 2 genes differen-
tially expressed in VSMCs from IMA versus SV as defined by
a more than 2-fold difference in expression level and statistical
significance (P0.05), namely tissue factor (TF; F3) and t-PA
(tPA; PLAT). Expression of TF was 3.1-fold lower in VSMCs
from IMA than SV (P0.006), whereas that of tPA was 9.0-fold
higher in IMA than SV (P0.001). In contrast to tPA, expres-
sion of urokinase-type plasminogen activator (uPA) was not
altered in VSMCs from SV as compared to IMA (n9; PNS).
Expression of tissue factor pathway inhibitor (TFPI), the
physiological inhibitor of TF, and plasminogen activator inhib-
itor (PAI)-1, the endogenous antagonist of tPA, was assessed as
well. Analysis of the 5 TFPI probe sets revealed very small
differences in expression between IMA and SV; the average
expression level was 1.2-fold lower in IMA as compared to SV.
This difference was not significant in 4 of the 5 probe sets (n9;
PNS), while reaching significance in 1 probe set (n9;
Figure 1. Expression of 54675 probe
sets is analyzed in vascular smooth
muscle cells from internal mammary
artery (IMA) and saphenous vein (SV) by
the human genome U133 Plus 2.0 array.
31 genes are directly involved in coagu-
lation; 2 of them are differentially
expressed: tissue factor (F3) and tissue
plasminogen activator (PLAT).
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P0.05; Figure 2A). The 3 PAI-1 probe sets exhibited minor
differences in mRNA expression between IMA and SV VSMCs;
the average expression level in IMA was 1.5-fold higher than in
SV, and this difference was significant in all the probe sets
(P0.05; Figure 2B).
Validation of Microarray Data at the mRNA
and Protein Level
TF mRNA expression was analyzed by real-time PCR and
observed to be 3.41.0-fold lower in VSMCs from IMA as
compared to SV (n4; P0.05; Figure 3A, upper panel). The
increase in TF mRNA expression after thrombin stimulation
reached 2.6-fold in IMA and 1.9-fold in SV VSMCs as com-
pared to basal level (n4; P0.01 for IMA and P0.01 for
SV). Real-time PCR also confirmed higher tPA mRNA expres-
sion in VSMCs from IMA as compared to SV (6.1-fold
difference; n4; P0.001; Figure 3B, upper panel). Stimulation
with thrombin did not affect the expression of tPA in VSMCs
from IMA or SV (n4; PNS).
Western blot analysis for TF protein expression revealed a
4.20.5-fold lower TF protein expression in VSMCs from IMA
as compared to SV (n5; P0.001; Figure 3A, middle panel).
Similarly, cellular TF activity (cytoplasmic and membrane) was
1.41.9 pmoles in IMA and 29.03.1 in SV (n5; P0.005;
Figure 3A, lower panel). The increase in TF protein expression
after thrombin stimulation was comparable in VSMCs from
IMA (1.80.4-fold; n5) and SV (2.10.7-fold; n5), and the
expression level was 5.21.6-fold lower in IMA as compared to
SV under these conditions (n5; P0.05). tPA protein levels
were 2.60.4-fold higher in the supernatant of VSMCs from
IMA as compared to SV (n3; P0.01; Figure 3B, middle
panel), reaching 20.54.8 ng/mL in IMA and 3.31.8 ng/mL in
SV (n7; P0.01; Figure 3B, lower panel). Stimulation with
thrombin did not affect tPA levels in VSMCs from IMA and SV
(n3; PNS).
Modulation of Coagulation by VSMCs
From IMA and SV
The functional relevance of the different gene expression
profile in VSMCs from IMA and SV was assessed. VSMCs
were first serum-starved for 48 hours, and after this time
period, cell supernatant was added to citrated human plasma
followed by analysis of clotting time. When supernatant from
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Figure 2. Expression profile of tissue fac-
tor (TF), t-PA (tPA), tissue factor pathway
inhibitor (TFPI), and plasminogen activator
inhibitor-1 (PAI-1) in vascular smooth
muscle cells from internal mammary
artery (IMA) and saphenous vein (SV).
IMA SV
TF
 m
R
N
A
 (%
)
0
100
200
300
400
500 *
0
30
60
90
120
*
0
30
60
90
120
*
0
100
200
300
400
500 *
IMA SV
tP
A
 m
R
N
A
 (%
)
MA SV
TF
 P
ro
te
in
 (%
)
IMA SV
tP
A
 P
ro
te
in
 (%
)TF
aT
0
10
20
30
*
IMA SV
tP
A
 P
ro
te
in
 (n
g/
m
l)
IMA SV
0
10
20
30
40
*
IMA SV
TF
 A
ct
iv
ity
 (p
m
ol
)
BA
Figure 3. Validation of microarray data in vascular smooth mus-
cle cells (VSMCs) from internal mammary artery (IMA) and
saphenous vein (SV) at the mRNA level (upper panels) by real
time-PCR and protein level (middle and lower panels) by West-
ern blotting or ELISA.
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IMA was compared to SV, TF protein was lower (39.020.4
versus 95.333.1 pg/mL; n5; P0.05; Figure 4A) in an
ELISA, TF activity was lower (10.71.4 versus 18.62.7
pmol; n6; P0.05; Figure 4B), TFPI protein was higher
(6.01.4 versus 4.41.3 ng/mL; n6; P0.05; Figure 4C),
and tPA protein was higher (Figure 3B). Consistent with
these findings, clotting time was prolonged in the presence of
supernatant from IMA (20829 seconds) as compared to SV
(11716 seconds; n4; P0.05; Figure 4D).
Migration of VSMCs From IMA and SV
TF surface expression was slightly lower in VSMCs from
IMA as compared to SV (Figure 5A). Similarly, TF surface
activity was 1.4-fold lower in IMA (n6; PNS; Figure 5B).
Migration in response to the TF/FVIIa complex (109 mol/L)
was 3.0-fold lower in VSMCs from IMA as compared to SV
(n4; P0.01; Figure 5C). PAR-2 protein expression was
similar in both cell types (n4; PNS; data not shown). A
PAR-2 cleavage blocking antibody did not affect the response
of VSMCs to TF/VIIa (n4; PNS; data not shown).
Discussion
This study demonstrates that, among the genes of the coagula-
tion system, only TF and tPA are differentially expressed in
VSMCs from IMA versus SV. TF, the key protein for thrombus
initiation, was expressed at a lower level in IMA VSMCs,
whereas tPA, a major regulator of fibrinolysis, was expressed at
a higher level in these cells. Consistently, conditioned media
from IMA VSMCs induced a smaller reduction in clotting time
of human plasma than media from SV. Moreover, IMA VSMCs
responded to TF/FVIIa by a weaker migration than those from
SV. These data demonstrate that IMA VSMCs exhibit intrinsic
functional differences as compared to those from SV regarding
the regulation of coagulation and vascular remodeling, and,
although performed in vitro, offer an explanation for the protec-
tion of IMA from thrombosis and bypass graft disease. Although
VSMCs were isolated from patients with coronary artery dis-
ease, neither IMA nor SV exhibited any atherosclerosis; hence,
their properties reflect primary intrinsic differences and may be
present in individuals without any atherosclerosis as well.
Moreover, the properties of IMA do not seem to extend to other
arteries, because it is unique in its resistance toward atheroscle-
rosis, whereas veins in general may be similar to the SV.
As the major initiator of coagulation, TF plays an important
role in the pathogenesis of thrombosis. Increased levels of TF
antigen are detectable in atheroma of patients with acute coro-
nary syndromes16; moreover, TF plasma levels are enhanced
during and after coronary artery bypass surgery, suggesting that
TF is involved in early graft occlusion.17–19 This study demon-
strates that VSMCs from IMA express less TF than those from
SV at both the RNA and the protein level.20,21 Although the
difference in TF expression is smaller and may have less
functional consequences than that in tPA expression, the lower
TF expression in IMA VSMCs may protect this vessel from
thrombotic occlusion if an endothelial erosion or denudation
occurs, which is particularly important in the early postoperative
phase. Indeed, IMA exhibits a dual protection from thrombus
formation, as it cannot only be prepared with less endothelial
damage, but its subendothelial gene expression profile is less
thrombogenic than that of the SV, where endothelial damage
during surgical preparation is extensive.
Tissue factor activity is counterbalanced by its endogenous
inhibitor, TFPI. In human arteries, TFPI diminishes throm-
bogenicity of atherosclerotic plaques and reduces fibrin as
well as platelet deposition.22 TFPI release was higher in
VSMCs from IMA than SV; hence, the lower TF expression
in IMA is not counteracted by a parallel decrease in TFPI and
therefore would be expected to represent a true protecting
factor in IMA. Because endothelial cells are a major source of
TFPI, they may modulate the balance of TF and TFPI;
however, these cells are difficult to isolate in sufficient
numbers from human bypass vessels.
Subacute or late occlusion of coronary artery bypass grafts
occurs as a result of migration and proliferation of VSMCs
leading to neointimal growth and the accelerated formation of
atherosclerotic lesions.6 Besides activating the coagulation
cascade, TF is involved in regulating vascular remodelling.
Indeed, TF is the receptor for FVIIa and as such mediates
cellular responses like migration and proliferation of
VSMCs23–25; consistently, low TF expression induces less
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Figure 4. Modulation of clotting time of human plasma by
supernatant of vascular smooth muscle cells (VSMCs) from
internal mammary artery (IMA) and saphenous vein (SV). A,
TF protein. B, TF activity. C, TFPI protein. D, Clotting time.
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arterial remodeling in vivo. IMA VSMCs did not only exhibit
lower TF expression, but also lower migration in response to
TF, indicating that the IMA is protected from both thrombus
formation and vascular remodeling. PAR-2 has been de-
scribed to play a role in signaling the migratory response to
TF/FVIIa.24 However, VSMCs from IMA and SV exhibited
similar PAR-2 protein expression, and a PAR-2 cleavage
blocking antibody did not affect migration in response to
TF/VIIa; hence, this receptor does not seem to regulate
migration in response to TF/VIIa under our experimental
conditions. The slightly lower TF surface expression and
activity in IMA as compared to SV may only in part account
for the lower migration of IMA VSMCs; hence, additional
intrinsic differences in the regulation of migration may well
exist. This interpretation is consistent with the observation
that migration of IMA VSMCs is lower than that of SV in
response to PDGF BB as well.14 These properties may protect
the IMA from remodeling and neointima formation and
thereby promote the long-term success of IMA grafts.
Although it has been clearly demonstrated that the TF
cytoplasmic domain regulates arterial remodeling in vivo,13 it
is still a matter of discussion which signal transduction events
mediate this effect. Indeed, TF/VIIa was observed to activate
the MAP kinases extracellular signal regulated kinase (ERK)
and p38, the GTPase Rac1, and different Src family mem-
bers.25–27 The role of these mediators in regulating TF/VIIa-
induced migration of VSMCs from human bypass vessels is
not known and should be investigated in additional studies.
Antithrombotic mechanisms of vascular cells include the
expression of tPA, a fibrinolytic enzyme mediating the
conversion of plasminogen to plasmin. tPA indeed induces
such an effective thrombolysis that its recombinant forms
have several therapeutic indications.28 This study reveals that
tPA is expressed at a much higher level in VSMCs from IMA
as compared to SV. VSMC supernatant from IMA indeed
exerted a lower acceleration of clotting time than supernatant
from SV, and this effect seems to be induced by a lower
release of TF and a concomitant higher release of TFPI as
well as tPA in IMA. These observations suggest a protective
role of tPA in IMA. In line with this interpretation, adenoviral
tPA gene transfer inhibits thrombus formation and promotes
vessel patency in different models of vascular injury.29,30
Hence, the higher tPA production in IMA VSMCs may be
equally important for preventing thrombotic events and main-
taining graft patency as its lower TF expression.
PAI-1 is a SERPIN that suppresses fibrinolysis by inhib-
iting the activity of tPA31; thus, excess PAI-1 activity would
be expected to overcome the actions of tPA and increase the
risk of thrombosis. However, in this study, PAI-1 gene
expression was only slightly higher in VSMCs from IMA as
compared to SV, indicating that the antithrombotic action of
tPA in the IMA grafts is, if at all, to only a minor extent
compensated by a concomitant increase in PAI-1 expression.
There is conflicting evidence on the functional role of tPA as
a migration modulating factor. Some in vitro studies suggest that
tPA stimulates VSMC migration, whereas others indicate that
tPA induces migration only in the presence of plasminogen.
More recent in vivo research reveals that tPA plays no role or
has even a beneficial effect on neointima formation32; moreover,
in vivo knockout models indicate that urokinase-type plasmin-
ogen activator (uPA), but not tPA, stimulates neointima forma-
tion.33 No difference in expression of plasminogen or uPA was
observed between VSMCs from IMA and SV, indicating that
the effect elicited by the higher tPA production in IMA is not
modulated by a concomitant difference in the expression of these
fibrinolytic proteins. Further, fibrinolysis rather than facilitation
of migration seems to represent the relevant action of tPA in
bypass graft disease, as the IMA is resistant against both
thrombotic occlusion and neointima formation, and this inter-
pretation is consistent with in vivo studies on the role of tPA in
vascular remodeling.33 Moreover, because of intrinsic differ-
ences in the regulation of chemotaxis, VSMCs from IMA
exhibit less migration than those from SV in response to
mediators as different as PDGF BB and TF/FVIIa; hence, these
cells would be expected to exhibit a weak migration even if tPA,
despite of all the existing evidence, stimulated VSMC migration
in bypass vessels.
In conclusion, this study suggests that the IMA is protected
from thrombosis and neointima formation by an impaired TF
expression in combination with an enhanced tPA production.
Although these differences elucidate some properties of IMA,
additional studies are required to fully understand the resis-
tance of this vessel toward atherosclerosis. Nevertheless,
these observations raise the question of whether a local
genetic anticoagulant treatment should be considered in
patients with venous bypass grafts in addition to systemic
antiplatelet therapy. This question, however, remains to be
answered in appropriately designed clinical trials.
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impaired PDGF-BB-induced stress fiber formation in MA and 
SV.  Conclusions: VSMC migration to PDGF-BB is lower in MA 
than SV, which is at least in part related to lower activity of 
the Rho/ROCK pathway.  Copyright © 2007 S. Karger AG, Basel 
 Introduction 
 Internal mammary artery (MA) and saphenous vein 
(SV) are used as conduits for coronary artery bypass 
grafting. Long-term patency rates of MA grafts, however, 
are higher than those of SV, with more than 85% of MA 
grafts patent after 10 years as compared to less than 50% 
of SV grafts  [1–3] . As a consequence, morbidity and mor-
tality are increased in patients receiving only venous 
grafts  [1, 2, 4] . Graft occlusion occurs due to thrombosis, 
neointima formation, and accelerated atherosclerosis  [2, 
5] . Although the frequency of acute thrombotic bypass 
graft occlusion has declined since the introduction of 
platelet inhibitory drugs, bypass graft disease remains a 
major problem  [4] .
 Vascular smooth muscle cell (VSMC) migration plays 
an important role in the development of neointima for-
mation and atherosclerotic lesions  [6, 7] ; hence, it is also 
 Key Words 
 Cell migration   Signal transduction   Atherosclerosis   
Bypass graft disease 
 Abstract 
 Background: We examined whether vascular smooth mus-
cle (VSMC) or endothelial cell (EC) migration from internal 
mammary artery (MA) differed from VSMC or EC migration 
from saphenous vein (SV).  Methods and Results: Migration 
to PDGF-BB (1–10 ng/ml) was lower in VSMC from MA than 
SV; however, attachment, movement without chemokine, 
and chemokinesis were identical. Unlike VSMC, migration of 
EC was similar in response to several mediators. Expression 
of PDGF receptor-  was lower in VSMC from MA than SV, 
while   -receptor expression was higher. PDGF-BB-induced 
RhoA activity was lower in MA than SV, while basal activity 
was identical. Rosuvastatin and hydroxyfasudil impaired 
PDGF-BB-induced migration of VSMC from MA and SV. Mev-
alonate and geranylgeranylpyrophosphate rescued inhibi-
tion by rosuvastatin. PDGF-BB induced less stress fiber for-
mation in VSMC from MA than SV. A dominant negative RhoA 
mutant inhibited stress fiber formation to PDGF-BB, while a 
constitutively active mutant resulted in maximal stress fiber 
formation in MA and SV. Rosuvastatin and hydroxyfasudil 
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involved in the pathogenesis of bypass graft disease  [8, 9] . 
The remarkable patency of MA grafts appears to be re-
lated to intrinsic functional properties  [10, 11] . Indeed, 
proliferation rates are lower in VSMC from MA than SV 
 [12] . However, migration rates of VSMC from these ves-
sels have not yet been compared.
 Endothelial cells (EC) are important regulators of vas-
cular homeostasis. Endothelial erosions are a frequent 
event in atherogenesis, as the absence of a complete en-
dothelial lining favors thrombus formation  [13] . Migra-
tion of EC is required for repair of eroded areas and as 
such is an important protective mechanism. Since migra-
tion rates of EC from MA versus SV are not known, the 
relevance of endothelial migration for patency of these 
grafts remains unclear.
 Therefore, the present study was designed to compare 
for the first time migration of VSMC as well as EC from 
MA versus SV.
 Methods 
 Cell Culture 
 VSMC of MA and SV were isolated from patients undergoing 
coronary artery bypass grafting, which was approved by the Eth-
ics Committee of the University Hospital. Isolation was per-
formed by the explantation method; each isolate was identified as 
VSMC by immunofluorescent staining for smooth muscle   -ac-
tin (No. 1148818, Roche Diagnostics, Mannheim, Germany). 
Cells were grown in Dulbecco’s MEM supplemented with 10% 
fetal calf serum (FCS) as described and used up to passage 12  [14] . 
EC isolation was performed enzymatically; each isolate was iden-
tified as EC by immunofluorescent analysis of acLDL uptake. 
Cells were grown in EGM-2 supplemented with 10% FCS (all from 
Cambrex Corporation, East Rutherford, N.J., USA) and used up 
to passage 5  [14] . Cells from MA and SV were only compared 
when they originated from the same patient and reached the same 
passage. Lactate dehydrogenase release was analyzed by a Cyto-
toxicity Detection Kit (Roche Diagnostic GmbH, Mannheim, 
Germany) as described in a previous study  [15] .
 Cell Migration and Attachment 
 Migration was examined in a modified Boyden chamber 
(Neuroprobe, Gaithersburg, Md., USA). For chemotaxis, the di-
rectional movement of cells towards a chemokine concentration 
gradient, different concentrations of PDGF-BB (R&D Systems, 
Minneapolis, Minn., USA), FCS, VEGF, or bFGF were diluted in 
PBS + 0.1% BSA and added to the lower compartment  [16] . For 
chemokinesis, the random movement of cells in the absence of 
any concentration gradient, PDGF-BB was added to both com-
partments. For movement without chemokine, 0.1% BSA was 
added to both compartments  [16] . Fifty microliters of the cell sus-
pension (5  ! 10 5  cells/ml) were placed in the upper compartment. 
The chambers were incubated at 37° for 5 h; then the upper sur-
face of the filter was scraped off. The cells were fixed in 100% 
methanol for 10 min and stained with Diff-Quick solution (Dade 
Diagnostics, Auckland, New Zealand). The number of migrated 
cells was counted at 400 ! magnification. To assess migration in 
the presence of hydroxyfasudil or rosuvastatin, VSMC were pre-
treated for 30 min with the respective inhibitor.  For examining 
attachment, subconfluent VSMC were seeded on 6-well tissue 
culture dishes and incubated with PDGF-BB for 5 h; afterwards, 
cells were washed with PBS and the number of attached cells de-
termined by a hemacytometer.
 RhoA Activity and Expression 
 VSMC were stimulated with PDGF-BB for 30 min and then 
lysed in buffer as described previously  [17] . Protein concentration 
was determined using the Bio-Rad protein assay (Bio-Rad, Mu-
nich, Germany). Western blotting and RhoA pulldown were per-
formed as described  [18] . The antibodies against RhoA, PDGF 
receptor-  (PDGFR-  ), PDGFR-  were obtained from Santa 
Cruz Biotechnology (Santa Cruz, Calif., USA) and that against 
  -tubulin from Sigma Chemical Company. 
 Adenoviral Transduction and Immunofluorescence 
 Adenoviral vectors for overexpression of constitutively active 
RhoA (Rho 63) and dominant negative RhoA (Rho 19) were kind-
ly provided by Z. Yang (University of Fribourg, Switzerland)  [19] . 
Cells were transduced with the respective adenoviral vector at 
moi 800. After a 24-hour growth period, the cells were rendered 
quiescent for 48 h before stimulation with PDGF-BB (10 ng/ml) 
for 5 h. Hydroxyfasudil or rosuvastatin were added 30 min before 
stimulation with PDGF-BB. 
 After stimulation, cells were washed with ice-cold PBS, fixed 
in 4% paraformaldehyde for 20 min at room temperature, per-
meabilized with 0.5% Triton X-100 in PBS for 10 min, and washed 
3 ! with PBS. Stress fiber formation was visualized by staining for 
F-actin bundling  [20] . Cells were blocked with 1% BSA in PBS for 
20 min followed by incubation with 3.3   g/ml TRITC-phalloidin 
(Sigma, St. Louis, Mo., USA) for 30 min. Afterwards, the cells 
were again washed 3 ! with PBS, and DAPI staining was per-
formed as described previously  [21] .
 Statistics 
 Cells from MA and SV were only compared when they origi-
nated from the same patient. For all experiments, ‘n’ designates 
the number of patients. Comparison were performed with un-
paired Student’s t test. 
 Results 
 Migration of VSMC and EC 
 Migration of MA VSMC was 7.0  8 2.4% in response 
to 1 ng/ml, 20.1  8 4.4% to 3 ng/ml, and 32.1  8 8.4% to 
10 ng/ml PDGF-BB ( fig. 1 a; p  ! 0.05 for 1 vs. 10 ng/ml). 
In contrast, migration of SV VSMC reached 44.7  8 8.5% 
in response to 1 ng/ml, 85.4  8 6.9% to 3 ng/ml, and 100% 
to 10 ng/ml PDGF-BB ( fig. 1 a; p  ! 0.0005 for 1 vs. 10 ng/
ml). Thus, migration to PDGF-BB was lower in VSMC 
from MA than SV and resulted in a significant difference 
between the two vessels at all PDGF-BB concentrations 
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examined (1 ng/ml: p  ! 0.005; 3 ng/ml: p  ! 0.0001; 10 
ng/ml: p  ! 0.0001;  fig. 1 a). No difference in attachment, 
movement without chemokine, or chemokinesis of VSMC 
from MA as compared to SV was observed (p = n.s.; 
 fig. 1 b).
 Migration of EC from MA and SV was identical in re-
sponse to 10% FCS (MA: 43.8  8 5.7, SV: 50.4  8 7.2 cells/
hpf; n = 5; p = n.s.;  table 1 ). A similar pattern was ob-
served after stimulation with 10 ng/ml bFGF (MA: 13.2 
 8 2.2, SV: 14.1  8 1.8 cells/hpf; n = 5; p = n.s.;  table 1 ) or 
10 ng/ml VEGF (MA: 23.4  8 4.7, SV: 23.2  8 2.9 cells/hpf; 
n = 5; p = n.s.;  table 1 ). 
 PDGFR Expression 
 While VSMC express PDGFR-  and PDGFR-  , VSMC 
migration is known to be mediated by PDGFR-  activa-
tion  [22] . Expression of these receptors was examined by 
Western blot analysis. PDGFR-  expression was higher 
in VSMC from MA than SV (p  ! 0.0001), while PDGFR-
  expression was lower in VSMC from MA than SV (p  ! 
0.005;  fig. 2 a).
 Rho/ROCK Pathway and Migration 
 In addition to the different PDGFR expression, signal 
transduction of VSMC from MA and SV may differ per 
se. The Rho/ROCK pathway is involved in VSMC migra-
tion and lies downstream of PDGFR-   [9, 23] . Therefore, 
RhoA activity was determined in VSMC from MA and 
SV. Basal RhoA activity did not differ in VSMC from MA 
and SV (p = n.s.; n = 4;  fig. 2 b). Stimulation with PDGF-
BB only weakly increased RhoA activity over control con-
ditions in VSMC from MA (p = 0.08), while a pronounced 
activation occurred in cells from SV (p  ! 0.05). Consis-
tent with this observation, PDGF-BB-induced RhoA ac-
tivity was lower in VSMC from MA as compared to SV 
(p  ! 0.005,  fig. 2 b).
 Rosuvastatin (10 –7  to 10 –5   M ), an inhibitor of RhoA 
activation, impaired PDGF-BB-induced migration of 
VSMC from MA and SV in a concentration-dependent 
manner (MA: 80.6  8 37.3% for 10 –7   M , 33.8  8 11.7% for 
10 –6   M , 29.6  8 11.9% for 10 –5   M ; n = 5; p  ! 0.01 for 10 –6  
and 10 –5   M ; SV: 67.3  8 5.2% for 10 –7   M , 46.5  8 4.6% for 
10 –6   M , 29.3  8 2.9% for 10 –5   M ; n = 5; p  ! 0.01 for 10 –7  to 
10 –5   M ;  fig. 3 ). The inhibitory effect of the statin was res-
cued by treatment of VSMC with 10 –4   M mevalonate (MA: 
72.0  8 9.0% for rosuvastatin + mevalonate vs. 27.8  8 
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 Fig. 1. Migration of VSMC from MA and SV.  a PDGF-BB induces 
lower migration rates of VSMC from MA as compared to SV.
 b No significant difference in attachment (left panel) or move-
ment without chemokine (right panel) is observed between VSMC 
from MA and SV. 
Chemotaxin MA EC SV EC p value
10% FCS, cell number/hpf 43.3985.73 50.4287.25 n.s.
10 ng/ml bFGF, cell number/hpf 13.2082.20 14.1481.75 n.s.
10 ng/ml VEGF, cell number/hpf 23.4084.65 23.1782.93 n.s.
EC migration is similar in response to 10% FCS, 10 ng/ml bFGF, and 10 ng/ml 
VEGF.
Table 1. Migration of EC from MA and 
SV
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9.3% for rosuvastatin alone, n = 4, p  ! 0.05; SV: 95.7  8 
4.6% for rosuvastatin + mevalonate vs. 42.3  8 4.0% for 
rosuvastatin alone, n = 4, p  ! 0.001;  fig. 3 ). A similar res-
cue was achieved with 10 –4   M geranylgeranylpyrophos-
phate (GGPP; n = 4;  fig. 3 ). Hydroxyfasudil (10 –5   M ), an 
inhibitor of ROCK activation, also inhibited PDGF-BB-
induced migration of VSMC from MA and SV (MA: 87.3 
 8 8.3% inhibition; SV: 87.4  8 5.9% inhibition; n = 4; 
p  ! 0.0001 vs. control for both vessels). Movement with-
out chemokine of VSMC from MA and SV was inhibited 
by both 10 –5   M rosuvastatin (MA: 38.0  8 8.8% inhibition, 
SV: 54.0  8 13.7% inhibition, p  ! 0.01 vs. control for both 
vessels) and 10 –5   M hydroxyfasudil (MA: 66.0  8 2.0% 
inhibition, SV 63.0  8 1.4% inhibition; p  ! 0.0001 vs. con-
trol for both vessels). No cytotoxic effect of any of these 
drugs was observed (n = 4; p = n.s.; data not shown).
 Rho/ROCK Pathway and Stress Fiber Formation 
 Stress fiber formation in VSMC is regulated by the 
Rho/ROCK pathway  [24] . In order to confirm the differ-
ential RhoA activation in VSMC from MA and SV, stress 
fiber formation was investigated in these cells. Consistent 
with the pattern of RhoA activation, stress fiber forma-
tion after stimulation with PDGF-BB was less pronounced 
in VSMC from MA than SV ( fig. 4 ). Adenoviral trans-
duction of a dominant negative RhoA mutant (Rho19) 
inhibited stress fiber formation in response to PDGF-BB 
in VSMC from MA and SV ( fig. 4 a). A constitutively ac-
tive RhoA mutant (Rho63) induced pronounced stress 
fiber formation in VSMC from MA and SV both in the 
presence or absence of PDGF-BB ( fig. 4 a). Transduction 
with a control vector (  E1) did not affect stress fiber for-
mation in VSMC from either vessel ( fig. 4 a). Similar to 
the dominant negative RhoA mutant, pharmacologic in-
hibition of RhoA with rosuvastatin and ROCK with hy-
droxyfasudil impaired PDGF-induced stress fiber forma-
tion in VSMC from both MA and SV ( fig. 4 b).
 Discussion 
 VSMC migration is a key event in the pathogenesis of 
atherosclerosis and bypass graft disease  [6, 8, 9] . The 
present study demonstrates for the first time that migra-
tion is lower in VSMC from MA than SV, while it is sim-
ilar in EC from the two vessels. Since no difference in 
attachment, movement without chemokine, or chemoki-
nesis of VSMC is observed, the difference in motility oc-
curs only in the presence of a chemotactic gradient and 
hence is consistent with a true difference in migration. As 
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lower in VSMC from MA than SV.  b Basal RhoA activity is simi-
lar in VSMC from MA and SV. PDGF-BB (10 ng/ml) significant-
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RhoA activity after stimulation with PDGF-BB is more pro-
nounced in SV VSMC than MA VSMC. No change in total RhoA 
expression occurs. RhoA activity is normalized to total RhoA and 
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PDGF-BB is known to play a major role in atherogenesis 
and bypass graft disease, the lower migration rates of 
VSMC from MA are consistent with the atherosclerosis 
resistance of this vessel  [7, 25] .
 The vascular system is heterogenous not only in mor-
phological, but also in functional terms; indeed, VSMC 
from different vascular beds vary with respect to both 
aspects  [12, 26] , and the distribution of receptors along 
the vascular tree is particularly heterogenous  [27] . Hence, 
it is not surprising that PDGFR expression differs in 
VSMC from MA as compared to SV. Although PDGF-BB 
activates two receptors on VSMC, only PDGFR-  medi-
ates migration  [22] . Our observations demonstrate that 
PDGFR-  expression is lower in VSMC from MA than 
SV, which is indeed consistent with the lower migration 
rates of the arterial VSMC.
 Heterogeneity of VSMC at the receptor level does not 
exclude additional differences in signal transduction. 
Small GTPases of the Rho family play a crucial role in 
VSMC migration  [28] , and RhoA is a well-described in-
tracellular target of PDGF-BB located downstream of 
PDGFR-   [23] . Therefore, the lower RhoA activity ob-
served in VSMC from MA as compared to those from SV 
is consistent with both the lower migration rates and the 
lower PDGFR-  expression of MA. This is in contrast to 
ERK activation; a previous study, which did, however, not 
examine migration in VSMC from MA and SV, observed 
that PDGF-induced ERK activation was similar in these 
0
25
50
75
100
125
M
ig
ra
te
d
ce
ll
s/
h
p
f
(%
)
– + + + +
MA
PDGF-BB:
(10 ng/ml)
Rosuvastatin:
(–log )
Mevalonate:
(10 )
GGPP:
(10 )
M
M
M
–4
–4
b
–
–
–
–
–
–
+
–
–
+
+
–
+
–
+
0
25
50
75
100
125
M
ig
ra
te
d
ce
ll
s/
h
p
f
(%
)
– + + + +
SV
PDGF-BB:
(10 ng/ml)
Rosuvastatin:
(–log )
Mevalonate:
(10 )
GGPP:
(10 )
M
M
M
–4
–4
–
–
–
–
–
–
+
–
–
+
+
–
+
–
+
0
25
50
75
100
125
M
ig
ra
te
d
ce
ll
s/
h
p
f
(%
)
– + + + +
MA
PDGF-BB:
(10 ng/ml)
Rosuvastatin:
(–log )M
a
– – 7 6 5
0
25
50
75
100
125
M
ig
ra
te
d
ce
ll
s/
h
p
f
(%
)
– + + + +
SV
PDGF-BB:
(10 ng/ml)
Rosuvastatin:
(–log )M
– – 7 6 5
 Fig. 3. Statin inhibits migration of VSMC from MA and SV.  a Rosuvastatin induces a concentration-dependent 
inhibition of VSMC migration from MA and from SV.  b Mevalonate and GGPP rescue inhibition of migration 
by rosuvastatin in VSMC from MA and from SV. 
 Weiss  /Frischknecht  /Greutert  /Payeli  /
Steffel  /Lüscher  /Carrel  /Tanner  
J Vasc Res 2007;44:149–156154
 Smooth Muscle Cell Migration in Bypass 
Grafts 
J Vasc Res 2007;44:149–156 155
cells  [12] . Hence, these observations support the interpre-
tation that there are additional levels of heterogeneity be-
tween VSMC from MA and SV apart from that occurring 
at the receptor level.
 RhoA activation is also important for the assembly of 
actin stress fibers  [29–31] . A role for RhoA in stress fiber 
formation of VSMC from MA and SV was confirmed us-
ing overexpression of mutant forms of RhoA. Indeed, 
PDGF-BB-induced stress fiber formation was impaired 
when cells were transduced with a dominant negative 
RhoA mutant; conversely, abundant stress fiber assembly 
was detected after overexpression of a constitutively ac-
tive RhoA mutant. In line with this observation, stress 
fiber formation was also impaired by inhibition of RhoA 
or ROCK with rosuvastatin or hydroxyfasudil, respec-
tively. Hence, RhoA activation induces stress fiber forma-
tion in VSMC from human bypass vessels. Stimulation 
with PDGF-BB elicited only a weak increase in stress fi-
ber formation in VSMC from MA, while this effect was 
pronounced in VSMC from SV, demonstrating that the 
lower Rho A activity in VSMC from MA as compared to 
SV is reflected in a less pronounced stress fiber forma-
tion. This finding is consistent with the lower expression 
of PDGFR-  in VSMC from MA as compared to SV. The 
specific role of stress fiber formation in VSMC migration, 
however, remains somewhat controversial, and further 
studies are needed to clarify this issue  [30–33] .
 Inhibitors of RhoA such as HMG-CoA reductase in-
hibitors (statins) impair migration of SV VSMC as well as 
neointima formation in human SV  [9] . Similarly, the 
ROCK inhibitor hydroxyfasudil inhibits VSMC migra-
tion as well as intimal hyperplasia  [20] . As VSMC from 
SV exhibit higher migration rates and higher RhoA activ-
ity than those from MA, the present study implies that 
inhibition of VSMC migration by inhibitors of the Rho/
ROCK pathway may be beneficial for the treatment of 
bypass graft disease. Indeed, for the first time, statin 
treatment was shown to render VSMC from SV similar to 
those from MA in terms of both migration capacity and 
RhoA activity. A beneficial effect of statins in the setting 
of SV graft disease is underscored by the observation that 
such inhibitors can also impair vasospasm, a frequent 
problem with SV grafts  [31, 34] .
 Taken together, the present data indicate for the first 
time that migration in response to PDGF-BB is lower in 
VSMC from MA than SV, and that this difference occurs 
due to a lower PDGFR-  expression resulting in a lower 
RhoA activation. The latter is reflected in a lower stress 
fiber formation in VSMC from MA than SV. Given the 
importance of VSMC migration for the pathogenesis of 
bypass graft disease, these findings reveal an important 
and novel mechanism for the superior patency rates of 
MA grafts. Conversely, inhibition of the Rho/ROCK 
pathway by rosuvastatin or hydroxyfasudil may prove 
beneficial for the treatment and/or prevention of bypass 
graft disease.
 Acknowledgement 
 The authors thank Dr. Z. Yang, University of Fribourg, Swit-
zerland, for providing the adenoviral vectors for the constitutive-
ly active and dominant negative RhoA mutants.
 This study was funded by Swiss National Science Foundation 
(grant 3200B0-102232/1 to F.C.T. and grant 32-51069.97/2 to 
T.F.L.), Swiss Heart Foundation, Novartis Foundation, and 
 Schweizerische Rentenanstalt. 
 Fig. 4. Stress fiber formation in VSMC from MA and SV.  a PDGF-
BB-induced stress fiber formation is less pronounced in VSMC 
from MA than SV (upper panel). Transduction with a constitu-
tively active RhoA mutant induces stress fiber formation in both 
vessels (middle panel), while a dominant negative mutant pre-
vents stress fiber formation (lower panel).  b Preincubation with 
rosuvastatin (Ros, middle panel) or hydroxyfasudil (Fas, lower 
panel) prevents stress fiber assembly in VSMC from both MA and 
SV. Figures show representative sections; all pictures were taken 
at 200 ! magnification. 
 Weiss  /Frischknecht  /Greutert  /Payeli  /
Steffel  /Lüscher  /Carrel  /Tanner  
J Vasc Res 2007;44:149–156156
 References 
 1 Loop FD, Lytle BW, Cosgrove DM, Stewart 
RW, Goormastic M, Williams GW, Golding 
LA, Gill CC, Taylor PC, Sheldon WC, et al: 
Influence of the internal-mammary-artery 
graft on 10-year survival and other cardiac 
events. N Engl J Med 1986;  314:  1–6. 
 2 Nwasokwa ON: Coronary artery bypass 
graft disease. Ann Intern Med 1995;  123: 
 528–545. 
 3 Barner HB, Barnett MG: Fifteen- to twenty-
one-year angiographic assessment of inter-
nal thoracic artery as a bypass conduit. Ann 
Thorac Surg 1994;  57:  1526–1528. 
 4 Cameron A, Davis KB, Green G, Schaff HV: 
Coronary bypass surgery with internal-tho-
racic-artery grafts – effects on survival over 
a 15-year period. N Engl J Med 1996;  334: 
 216–219. 
 5 Lytle BW, Loop FD, Cosgrove DM, Ratliff 
NB, Easley K, Taylor PC: Long-term (5 to 12 
years) serial studies of internal mammary 
artery and saphenous vein coronary bypass 
grafts. J Thorac Cardiovasc Surg 1985;  89: 
 248–258. 
 6 Schwartz SM: Smooth muscle migration in 
atherosclerosis and restenosis. J Clin Invest 
1997;  100:S87–S89. 
 7 Ross R: Atherosclerosis – an inflammatory 
disease. N Engl J Med 1999;  340:  115–126. 
 8 Johnson JL, van Eys GJ, Angelini GD, George 
SJ: Injury induces dedifferentiation of 
smooth muscle cells and increased matrix-
degrading metalloproteinase activity in hu-
man saphenous vein. Arterioscler Thromb 
Vasc Biol 2001;  21:  1146–1151. 
 9 Porter KE, Naik J, Turner NA, Dickinson T, 
Thompson MM, London NJ: Simvastatin in-
hibits human saphenous vein neointima for-
mation via inhibition of smooth muscle cell 
proliferation and migration. J Vasc Surg 
2002;  36:  150–157. 
 10 Canham PB, Finlay HM, Boughner DR: 
Contrasting structure of the saphenous vein 
and internal mammary artery used as coro-
nary bypass vessels. Cardiovasc Res 1997;  34: 
 557–567. 
 11 Luscher TF, Diederich D, Siebenmann R, 
Lehmann K, Stulz P, von Segesser L, Yang 
ZH, Turina M, Gradel E, Weber E, Buhler 
FR. Difference between endothelium-de-
pendent relaxation in arterial and in venous 
coronary bypass grafts. N Engl J Med 1988; 
 319:  462–467 
 12 Yang Z, Oemar BS, Carrel T, Kipfer B, Julmy 
F, Luscher TF: Different proliferative prop-
erties of smooth muscle cells of human arte-
rial and venous bypass vessels: role of PDGF 
receptors, mitogen-activated protein kinase, 
and cyclin-dependent kinase inhibitors. Cir-
culation 1998;  97:  181–187. 
 13 Shah PK: Plaque disruption and thrombosis: 
potential role of inflammation and infec-
tion. Cardiol Rev 2000;  8:  31–39. 
 14 Steffel J, Akhmedov A, Greutert H, Luscher 
TF, Tanner FC: Histamine induces tissue 
factor expression: implications for acute cor-
onary syndromes. Circulation 2005;  112: 
 341–349. 
 15 Steffel J, Hermann M, Greutert H, Gay S, 
Luscher TF, Ruschitzka F, Tanner FC: Cele-
coxib decreases endothelial tissue factor ex-
pression through inhibition of c-Jun termi-
nal NH2 kinase phosphorylation. Circulation 
2005;  111:  1685–1689. 
 16 Degryse B, Bonaldi T, Scaffidi P, Müller S, 
Resnati M, Sanvito F, Arrigoni G, Bianchi 
ME. The high mobility group (HMG) boxes 
of the nuclear protein HMG1 induce chemo-
taxis and cytoskeleton reorganization in rat 
smooth muscle cells. J Cell Biol 2001;  152: 
 1197–1206. 
 17 Tanner FC, Boehm M, Akyurek LM, San H, 
Yang ZY, Tashiro J, Nabel GJ, Nabel EG: Dif-
ferential effects of the cyclin-dependent ki-
nase inhibitors p27(Kip1), p21(Cip1), and 
p16(Ink4) on vascular smooth muscle cell 
proliferation. Circulation 2000;  101:  2022–
2025. 
 18 Eto M, Kozai T, Cosentino F, Joch H, Luscher 
TF: Statin prevents tissue factor expression 
in human endothelial cells: role of Rho/Rho-
kinase and Akt pathways. Circulation 2002; 
 105:  1756–1759. 
 19 Viswambharan H, Ming XF, Zhu S, Hubsch 
A, Lerch P, Vergeres G, Rusconi S, Yang Z: 
Reconstituted high-density lipoprotein in-
hibits thrombin-induced endothelial tissue 
factor expression through inhibition of 
RhoA and stimulation of phosphatidylinosi-
tol 3-kinase but not Akt/endothelial nitric 
oxide synthase. Circ Res 2004;  94:  918–925. 
 20 Negoro N, Hoshiga M, Seto M, Kohbayashi 
E, Ii M, Fukui R, Shibata N, Nakakoji T, 
Nishiguchi F, Sasaki Y, Ishihara T, Ohsawa 
N: The kinase inhibitor fasudil (HA-1077) 
reduces intimal hyperplasia through inhib-
iting migration and enhancing cell loss of 
vascular smooth muscle cells. Biochem Bio-
phys Res Commun 1999;  262:  211–215. 
 21 Steffel J, Latini RA, Akhmedov A, Zimmer-
man D, Zimmerling P, Luscher TF, Tanner 
FC: Rapamycin, but not FK-506, increases 
endothelial tissue factor expression – impli-
cations for drug-eluting stent design. Circu-
lation 2005, in press. 
 22 Davies MG, Owens EL, Mason DP, Lea H, 
Tran PK, Vergel S, Hawkins SA, Hart CE, 
Clowes AW: Effect of platelet-derived growth 
factor receptor-alpha and -beta blockade on 
flow-induced neointimal formation in endo-
thelialized baboon vascular grafts. Circ Res 
2000;  86:  779–786. 
 23 Zubiaur M, Sancho J, Terhorst C, Faller DV: 
A small GTP-binding protein, Rho, associ-
ates with the platelet-derived growth factor 
type-beta receptor upon ligand binding. J 
Biol Chem 1995;  270:  17221–17228. 
 24 Mack CP, Somlyo AV, Hautmann M, Somlyo 
AP, Owens GK: Smooth muscle differentia-
tion marker gene expression is regulated by 
RhoA-mediated actin polymerization. J Biol 
Chem 2001;  276:  341–347. 
 25 Abedi H, Zachary I: Signalling mechanisms 
in the regulation of vascular cell migration. 
Cardiovasc Res 1995;  30:  544–556. 
 26 Adams LD, Geary RL, McManus B, Schwartz 
SM: A comparison of aorta and vena cava 
medial message expression by cDNA array 
analysis identifies a set of 68 consistently dif-
ferentially expressed genes, all in aortic me-
dia. Circ Res 2000;  87:  623–631. 
 27 Hill CE, Phillips JK, Sandow SL: Heteroge-
neous control of blood flow amongst differ-
ent vascular beds. Med Res Rev 2001;  21:  1–
60. 
 28 Ridley AJ: Rho GTPases and cell migration. 
J Cell Sci 2001;  114:  2713–2722. 
 29 Ridley AJ, Hall A: The small GTP-binding 
protein rho regulates the assembly of focal 
adhesions and actin stress fibers in response 
to growth factors. Cell 1992;  70:  389–399. 
 30 Nobes CD, Hall A: Rho, rac, and cdc42 GT-
Pases regulate the assembly of multimolecu-
lar focal complexes associated with actin 
stress fibers, lamellipodia, and filopodia. 
Cell 1995;  81:  53–62. 
 31 Kato T, Hashikabe H, Iwata C, Akimoto K, 
Hattori Y: Statin blocks Rho/Rho-kinase sig-
nalling and disrupts the actin cytoskeleton: 
relationship to enhancement of LPS-medi-
ated nitric oxide synthesis in vascular 
smooth muscle cells. Biochim Biophys Acta 
2004;  1689:  267–272. 
 32 Pickering JG, Uniyal S, Ford CM, Chau T, 
Laurin MA, Chow LH, Ellis CG, Fish J, Chan 
BM: Fibroblast growth factor-2 potentiates 
vascular smooth muscle cell migration to 
platelet-derived growth factor: upregulation 
of alpha2beta1 integrin and disassembly of 
actin filaments. Circ Res 1997;  80:  627–637. 
 33 Fu M, Zhang J, Tseng YH, Cui T, Zhu X, Xiao 
Y, Mou Y, De Leon H, Chang MM, Hama-
mori Y, Kahn CR, Chen YE: Rad GTPase at-
tenuates vascular lesion formation by inhibi-
tion of vascular smooth muscle cell migra-
tion. Circulation 2005;  111:  1071–1077. 
 34 Shimokawa H: Rho-kinase as a novel thera-
peutic target in treatment of cardiovascular 
diseases. J Cardiovasc Pharmacol 2002;  39: 
 319–327. 
ORIGINAL ARTICLE
Endothelial Nitric Oxide Synthase Gene Transfer
Inhibits Human Smooth Muscle Cell Migration via
Inhibition of Rho A
Thomas Largiade`r, MD,* Masato Eto, MD, PhD,*† Sravan K. Payeli, MSc,* Helen Greutert, BSc,*
Hema Viswambharan, PhD,§ Mario Lachat, MD,‡ Gregor Zu¨nd, MD,‡ Zhihong Yang, MD,§
Felix C. Tanner, MD,*† and Thomas F. Lu¨scher, MD*†
Abstract: Smooth muscle cell (SMC) migration contributes to
vascular remodeling. Nitric oxide (NO) produced via endothelial
NO synthase (eNOS) inhibits SMC migration. This study analyzes
signal transduction mechanisms of SMC migration targeted by NO.
SMCs were cultured from human saphenous veins, and cell migration
was studied using Boyden chambers. PDGF-BB (0.1 to 10 ng/ml)
stimulated SMC migration in a concentration-dependent manner,
which was inhibited by adenoviral-mediated overexpression of eNOS
and by the NO donor diethylentriamine NONOate (DETANO, 10-5 to
10-3 mol/L). NO release was enhanced in eNOS-transduced SMCs,
and L-NAME blunted the effect of eNOS overexpression on
migration. PDGF-BB (10 ng/ml) activated Rho A, which was
inhibited by the overexpression of eNOS by DETANO and by
8 bromo-cGMP. The inhibitory effect of DETANO on Rho A activity
was prevented by the cGMP-dependant kinase inhibitor. Furthermore,
inhibition of Rho A by C3 exoenzyme and inhibition of ROCK by
Y-27632 diminished cell migration stimulated by PDGF-BB. Finally,
in the cells overexpressing constitutively active ROCK mutant (CAT),
DETANO failed to prevent PDGF-BB–induced SMC migration. In
conclusion, NO inhibits human SMC migration via blockade of the
Rho A pathway.
Key Words: gene transfer, nitric oxide, eNOS, smooth muscle cell
migration
(J Cardiovasc PharmacolTM 2008;0:000–000)
INTRODUCTION
Migration of smooth muscle cells (SMCs) is an essential
event in vascular remodeling and thus in the development of
vascular diseases such as atherosclerosis, restenosis, and
bypass vein graft disease.1–3 Many growth factors such as
PDGF, bFGF, and thrombin are potent mediators of cell
migration.4–6 Although an interaction of SMCs with extracel-
lular matrix has been shown to play an important role in SMC
migration,7 intracellular signal transduction pathways acti-
vated by migratory stimuli are mostly undefined.
Stimulation of SMCs with growth factors or chemo-
attractants is associated with activation of an array of signal
transduction pathways including p44/p42mapk, p70S6K, and
the small GTP binding protein Rho GTPases activated
either through tyrosine kinase receptors or G-protein coupled
receptors.8–10 These molecules transmit extracellular growth
signals into the cell nucleus, thereby activating transcription
factors and regulating downstream gene expression and
cellular responses. The Rho GTPases form a novel subgroup
of the Ras superfamily of 20- to 30-kDa GTP-binding proteins.
Rho GTPases function as molecular switches, cycling between
an inactive GDP-bound state and an active GTP-bound state
and are involved in transcriptional regulation and cell
proliferation/migration control. Rho A is one member of
a distinct group of Rho-like proteins.10
NO produced from L-arginine via endothelial nitric
oxide synthase (eNOS) is a potent vasodilator, platelet
inhibitor, and reduces SMC proliferation and migration.11,12
NO can affect proteins involved in cell cycle regulation and in
turn induce cell cycle arrest.13–15 However, it is still unclear
through which signal transduction pathways NO regulates
SMC migration. Therefore, the aim of this study focused
on the intracellular signal transduction pathways of cell migra-
tion targeted by NO in human SMCs, with particular emphasis
on Rho A pathway.
METHODS
Materials
All materials for cell culture were purchased from
GibcoBRL (Basel, Switzerland). Clostridium Botulinum
C3 exoenzyme,16 DietylentriamineNONOate (DETANO),17
and KT582318 were from Calbiochem (Luzern, Switzerland).
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Rabbit polyclonal antibodies against phospho-p44/p42mapk
and phospho-p70S6K were from New England BioLabs
(Allschwil, Switzerland); Rho A (SC-119) was purchased
from Santa Cruz Biotechnology Inc. (Basel, Switzerland).
Mouse monoclonal antibody against human eNOS (N30020)
was from Transduction Laboratories (Basel, Switzerland). The
ROCK inhibitor Y-2763216 was kindly provided by Welfide
Corporation, Osaka, Japan.
Recombinant Adenovirus
An adenoviral vector for expression of human placental
alkaline phosphatase (AdhpAP) and a control virus without
transgene (AdDE1) were derived from Ad5 sub360 and pre-
pared as described.19 A similar virus for expression of eNOS
(adeNOS) was provided by Dr. Stephan Janssens, Leuven,
Belgium. Expression of adeNOS was driven by a CMV pro-
moter, while the AdDE1 had no insert (for details see refer-
ence 15). Adenoviral vectors for expression of constitutively
active ROCK mutant (CAT) and LacZ were generated using
the CMV promoter in the pEF-BOS-myc-RB/PH (TT) vector
as described elsewhere.20 The titer of purified viruses was
determined by plaque assay on 293 cells.
Culture of Human SMCs
SMCs were cultured from saphenous veins (SVs)
obtained from patients undergoing coronary bypass surgery
using an explant technique.21 The patients gave informed
consent in accordance with the Declaration of Helsinki. The
cells were cultured in DMEM containing 20% FCS
supplemented with 20 mmol/l L-glutamine and 10 mmol/l
HEPES buffer solution, 100 U/ml penicillin, and 100 mg/ml
streptomycin in a humidified atmosphere (95% air/5% CO2) at
37C. Culture medium was replaced every 3 days. Cells were
passaged by cell dissociation solution. Experiments were
performed on passage 4–7. SMCs were characterized by their
typical morphological pattern and by indirect immunofluo-
rescence staining by using specific mouse monoclonal
antibodies against human SMC a-actin.21
Gene Transfer
SMCs were incubated with a viral titer of 1000 pfu/cell
for 1 hour in DMEM containing 2% FCS at 37C in
a humidified atmosphere and then kept in DMEM with 10%
FCS for 24 hours. The transfer efficiency was analyzed using
AdhpAP and determined 24 hours after infection by fixing the
cells in 1.25% glutaraldehyde (Sigma, Buchs, Switzerland)
and staining with NBT/BCIP (GIBCO) as described.19 The
eNOS expression was analyzed by Western blot. The cells for
further experiments were then kept in serum-free medium for
24 to 48 hours. SMCs infected with AdDE1 or LacZ and
uninfected cells served as negative controls for all experiments.
Migration Assay
Vascular smooth muscle cells were grown to confluence
in DMEM medium supplemented with 10% fetal bovine
serum. Cells were detached from the plate by trypsinization,
and migration efficiency was tested using a 48-well Boyden
chamber (Neuroprobe Inc., Cabin John, MD) in the presence
of 10 ng/ml PDGF as a chemotactic agent. A total of 25,000
cells per group were used for migration experiments. For
adenoviral transduction, cells were seeded at 40% confluence
and left in the incubator for 24 hours. Cells were transfected as
described and treated with or without the eNOS inhibitor
L-NAME, the Rho A inhibitor exoenzyme-C3 or the ROCK
inhibitor Y-27632 at indicated concentrations for 30 minutes.
Cells were allowed to migrate for 5 hours at 37C/5%CO2.
Nonmigrated cells were removed from the upper side with
a cell scraper, and migrated cells from the bottom side were
fixed in ice-cold methanol, stained with Diffquick solution
I and II (Medion Diagnostics, switzerland), and counted on
4 different fields as described.22
Activation of p44/42mapk and p70s6k
Quiescent human saphenous vein SMC rested in serum-
free medium for 48 hours were stimulated with PDGF-BB
(10 ng/ml). After stimulation, the cells were washed with ice-
cold PBS and harvested with cold extraction buffer (120 mmol/l
sodium chloride, 50 mmol/l Tris, 20 mmol/l sodium fluoride,
1 mmol/l benzamidine, 1 mmol/l DTT, 1 mmol/l EDTA,
6 mmol/l EGTA, 15 mmol/l sodium pyrophosphate, 0.8 mg/ml
leupeptin, 30 mmol/l p-nitrophenylphosphate, 0.1 mmol/l
PMSF, and 1% Nonidet P40). Twenty micrograms of
cell extracts were boiled at 95C for 10 minutes in Laemmli
SDS-PAGE sample buffer (50 mmol/l Tris-Cl, 100 mmol/l
DTT, 2% SDS, 0.1% bromophenol blue, and 10% glycerol)
and subjected to 10% SDS-PAGE gels for electrophoresis.
Proteins were then transferred onto Immobilon-P filter papers
(Millipore AG) with a semidry transfer unit. Equal loading was
controlled by staining with Ponceau S. Membranes were then
blocked by 5% skim milk in PBS-Tween buffer (0.1% Tween
20) for 1 hour and incubated with the primary antibodies (the
anti-phospho-p44/42mapk antibody, 1:1000; anti-phospho-p70S6K
antibody, 1:1000). The immunoreactive bands were detected
by use of an enhanced chemiluminescence (ECL) system
(Amersham).
Rho A Membrane Translocation
Confluent and quiescent SMCs were stimulated with
PDGF-BB (10 ng/ml). The cells were then washed twice with
cold PBS and then harvested in PBS buffer containing
2 mmol/l EDTA, 2 mmol/l phenylmethylsulfonyl fluoride, and
1 mmol/l leupeptin. The cells were then disrupted by brief
sonication on ice. The samples were then centrifuged at 5003 g
for 10 minutes at 4oC to remove the nucleus. The membrane
and cytosolic portions were then separated by centrifugation at
100,000 3 g for 1 hour at 4oC (Airfuge; Beckman Instru-
ments, Inc., Nyon, Switzerland). The cell membranes were
washed once with the above-mentioned buffer and then
resuspended in buffer containing 100 mmol/l Tris-HCl,
300 mmol/l NaCl, 1% Triton X-100, and 0.1% SDS containing
2 mmol/l EDTA, 2 mmol/l PMSF, and 1 mmol/l leupeptin.
Equal amounts of protein (10 mg) were loaded into 12% SDS-
PAGE gels and applied to electrophoresis. Western blot was
then performed with the antibody against Rho A (1:1000).
Rho A Activity
Rho A activity was determined by pull-down assay. The
cell lysates were incubated with agarose-conjugated Rhotekin
Rho Binding Domain (Upstate Biotechnology, Lake Placid, NY)
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for 45 minutes. The agarose beads were collected and run in
12% SDS-PAGE gels. Western blot was performed using the
antibody against Rho A.
Expression of eNOS
eNOS expression was analyzed by Western blot. The
SMCs were kept in DMEM containing 10% FCS for 24 hours
after transduction. Cells were then harvested with cold
extraction buffer, and 20 mg of protein was loaded on to
8% SDS-PAGE as described above. The eNOS antibody
(1:600) was used as the primary antibody.
Nitric Oxide Release
SMCs were grown in DMEM medium supplemented
with 10% fetal bovine serum. A total of 70,000 cells were
seeded in a 12-well plate at 40% confluence and incubated for
24 hours before transfection. After transfection, 10% DMEM
was replaced, and cells were incubated for additional 24 hours.
Cells were prepared according to the manufacturer’s instruc-
tions in the presence of DETC (Noxygen, Germany) and
FeSO4. Nitric oxide levels were measured with e-scan
(BRUKER). Data were calculated and represented in nano-
moles/minute/number of cells.
Statistical Analyses
Data are presented as mean 6 SEM. Rho A trans-
location was expressed as percent increase above control. In all
experiments, n equals the number of patients from which cells
were obtained; in the migration assay, every experiment was
done in triplicates. Statistical analyses were performed with
unpaired t test between 2 groups and analysis of variance among
more than 3 groups. P , 0.05 was considered significant.
RESULTS
Overexpression of eNOS Inhibits
SMC Migration
In cultured SMCs, PDGF-BB (0.1, 1, and 10 ng/ml)
stimulated cell migration in a concentration-dependent manner
(8 6 2, 28 6 3, and 76 6 4 cells/field of vision compared to
control 6 6 2; P , 0.05 for 1 and 10 ng/ml). Cell migration
stimulated by PDGF (10 ng/ml) was concentration depen-
dently inhibited by the NO donor, DETANO (F1 Figure 1A).
Overexpression of eNOS in SMCs was achieved with an
adenoviral vector. A viral titer of 1000 pfu/cell was used and
resulted in 99% transfected SMCs (data not shown). Expres-
sion of eNOS in SMCs was further evidenced by Western blot
(Figure 1B insert). eNOS overexpression significantly reduced
PDGF-induced cell migration (Figure 1B). Although the
control adenovirus (AdDE1) tended to have some inhibitory
effects, this did not reach statistical significance. Exposure of
SMCs to AdDE1 or AdeNOS did not exert any cytotoxic
effects as determined by LDH release (n = 3; P = not signifi-
cant; data not shown). Adenoviral overexpression of eNOS
enhanced NO release from SMCs (n = 4; P , 0.05; data not
shown). The inhibitory effect of adeNOS on SMC migration
was blunted by L-NAME (Figure 1C).
FIGURE 1. NO inhibits human SMC migration. (A) Treatment
of the cells with the NO donor DETANO (10-5 to 10-3 mol/l)
inhibited the migratory activity of SMCs in response to
PDGF-BB (10 ng/ml, 4 hours) in a concentration-dependent
manner. (B) Migration to PDGF-BB (10 ng/ml) was also
inhibited by adenoviral eNOS (AdeNOS) transfer. eNOS gene
expression in human SMCs was evidenced by Western blot
(insert, n = 4). (C) L-NAME (3 3 10-4 mol/L) blunted the effect
of AdeNOS on SMC migration. *P , 0.05 versus PDGF alone.
**P, 0.05 versus empty vector. †P, 0.001 versus PDGF alone.
‡P , 0.001 versus PDGF without L-NAME.
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NO Inhibits SMC Migration Via Inhibition of
Rho A
The cell migration stimulated by PDGF-BB was
associated with activation of various signal transduction
pathways such as Rho A, p44/42mapk, and p70s6k. PDGF-BB
(10 ng/ml) time-dependently stimulated Rho A membrane
accumulation, which is the crucial step for activation of the
GTPase (F2 Figure 2A). Activation of Rho A reached the
maximum at 30 to 60 minutes (Figure 2A). We could not
detect significant changes of Rho A in cytosolic fraction,
possibly due to a large amount of Rho A in cytoplasm. The
Rho A membrane accumulation stimulated by PDGF-BB
(10 ng/ml, 30 minutes) was prevented by DETANO (10-4
mol/l) (Figure 2B) and by eNOS overexpression (Figure 2C),
although the vector alone also had some nonsignificant effect.
Rho A activity was also evaluated with pull-down assay.
Similar to the membrane translocation assay, PDGF-BB
(10 ng/ml) also increased Rho A activity in SMCs, with the
maximal effect at 30 minutes after the stimulation (F3 Figure 3A).
Total Rho A amount was not affected by PDGF until
60 minutes. The increase in Rho A activity stimulated by
PDGF-BB (10 ng/ml, 30 minutes) was prevented by DETANO
(10-4 mol/l) and 8-bromo cGMP (10-4 mol/l) (Figure 3B). The
inhibition of cGMP-dependent kinase by KT5823 (10-7 mol/l)
blocked the suppressive effect of DETANO on Rho A activity
(Figure 3B).
In addition to Rho A, PDGF-BB also activated
p44/42mapk and p70s6k in cultured SMCs. PDGF-BB (10 ng/ml,
10 minutes) phosphorylated p44/42mapk and p70s6k as demon-
strated by Western blots using specific antibodies against
phospho-p44/42mapk and phospho-p70s6k. The NO donor
DETANO (10-4 mol/l) alone stimulated, rather than inhibited,
p44/42mapk, but it did not influence the activation of p44/42mapk
or p70s6k in response to PDGF-BB (10 ng/ml, data not shown).
Inhibition of Rho A and ROCK Inhibits
SMC Migration
The migratory activity of human SMCs stimulated by
PDGF-BB (10 ng/ml) was reduced by the Rho A inhibitor
50 mg/ml C3 exoenzyme ( F4Figure 4A) as well as by the
downstream kinase ROCK inhibitor Y-27632 (Figure 4B).
Overexpression of Constitutively Active ROCK
Mutant Blocks the Effect of NO
To get direct evidence that the inhibitory effect of NO on
SMC migration is mediated by inhibition of Rho/ROCK
pathway, we investigated the effect of overexpression of con-
stitutively active ROCK mutant (CAT). DETANO (10-4 mol/l)
again prevented PDGF-BB–induced SMC migration in
the cells infected with control adenoviruses for expression
of LacZ. On the other hand, DETANO failed to prevent
PDGF-BB-induced SMC migration in the cells overexpressing
constitutively active ROCK mutant (CAT) ( F5Figure 5).
FIGURE 2. Effects of NO on Rho Amembrane translocation. (A)
Membrane translocation of Rho A was stimulated by PDGF-BB
(10 ng/ml) in a time-dependent manner, which reached the
maximum at 30 minutes. (B and C) Rho A translocation in
response to PDGF-BB (10 ng/ml, 30 minutes) was reduced by
the NO donor DETANO (10-4 mol/l) or by adenoviral eNOS
gene transfer. *P , 0.05 versus PDGF alone. **P , 0.05 versus
empty vector.
FIGURE 3. Effects of NO on Rho A activity. (A) Activity of Rho A
determined by pull-down assay was stimulated by PDGF-BB
(10 ng/ml) in a time-dependent manner, which reached the
maximum at 30 minutes. (B) Rho A activity in response to
PDGF-BB (10 ng/ml, 30 minutes) was reduced by the NO
donor DETANO (10-4 mol/l) and 8-bromo cGMP (10-4 mol/l).
cGMP-dependent kinase inhibitor KT5823 blocked the inhib-
itory effect of DETANO on Rho A activity. Similar results were
obtained in 3 independent experiments.
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DISCUSSION
In human SMCs, NO provided by the overexpression of
eNOS gene with a recombinant adenovirus vector or added
directly through an NO donor inhibits the cell migration in
response to PDGF via inhibition of the Rho A pathway.
SMC migration essentially contributes to intimal thick-
ening and vascular remodeling in atherosclerosis, restenosis,
and venous bypass graft disease.1–3 Almost all peptide growth
factors, such as PDGF, are also important activators of SMC
migration.1–3 In this study, we selected PDGF as a migratory
signal and obtained concentration-dependent stimulation of
human SMC migration. We and the other group reported that
NO inhibits migration of rat and human arterial SMCs.11,12 We
used DETANO as a pharmacological source of NO because
this molecule exhibits very slow and prolonged release
kinetics of the free radical, which is most suitable for cell
culture experiments.21 Overexpression of eNOS provides
a novel concept for the inhibition of SMC proliferation and
migration in vascular diseases such as restenosis and venous
bypass graft disease.23–25 Using an adenoviral vector, we
successfully transferred eNOS into human vascular SMCs as
demonstrated by Western blot. Previous studies demonstrated
a very high transfer rate (99%) under these experimental
conditions,19 which was also achieved in the current experi-
ments. As in previous studies, the control virus did exert some
nonspecific effects; however, the pronounced effects of the
eNOS adenovirus can be blocked by L-NAME,15 demonstrat-
ing that NO indeed is involved.
Expression of eNOS in saphenous vein SMCs was
associated with important biological effects. Indeed, eNOS
gene transfer markedly reduced PDGF-induced migration of
SMCs. Although the empty virus tended to have some effects
as well, this did not reach statistical significance. PDGF-
induced migration of SMCs was associated with activation of
a series of intracellular signal transduction pathways such as
p44/42mapk, p70s6k, and Rho A. In particular, PDGF increased
the activity of Rho A as well as its membrane accumulation.
High local levels of NO provided either pharmacologically
with DETANO or via adenovirus-mediated eNOS gene
transfer reduced the activity and the translocation of Rho A.
In addition to Rho A, PDGF-BB also activated p44/42mapk
or p70s6k in cultured SMCs. However, NO did not inhibit
the activation of either p44/42mapk or p70s6k in response to
PDGF-BB, suggesting that the effects of NO on the RhoA
pathway are very specific. Evidence for the involvement of the
Rho A pathway as a mediator of the antimigratory effects of
NO was further strengthened by experiments with the specific
inhibitors and the constitutively active ROCK mutant. Indeed,
consistent with the report by the other group,26 the migratory
activity of PDGF in SMCs was reduced in the presence of the
FIGURE 4. Inhibition of Rho A and ROCK suppresses SMC
migration. PDGF-BB (10 ng/ml) increased the number of
migrated cells within 4 hours, which was inhibited (A) by a
specific Rho A inhibitor C3 exoenzyme (50 mg/ml) or (B) by a
downstream kinase ROCK inhibitor Y-27632 in a concentration-
dependent manner. *P , 0.05 versus PDGF alone.
FIGURE 5. Overexpression of constitutively active ROCK
mutant blocks the inhibitory effect of NO. In the cells
overexpressing active ROCK mutant (CAT), the inhibitory
effect of DETANO (10-4 mol/l) on SMC migration induced by
PDGF BB (10 ng/ml, 4 hours) was not observed. *P , 0.05
versus PDGF alone.
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Rho A inhibitor C3 exozyme27 as well as the ROCK inhitor
Y-2763228; conversely, the effects of NO were prevented by the
overexpression of constitutively active ROCK mutant (CAT).
In addition, we investigated the mechanistic insights into
how NO blocks Rho A activity. In general, the effects of NO
on cellular functions are mediated by cGMP-dependent and
independent mechanisms. We hypothesized that cGMP path-
way might mediate the inhibitory action of NO on Rho A
activity. Indeed, the cGMP analogue, 8-bromo cGMP pre-
vented the increase in Rho A activity stimulated by PDGF and
the cGMP-kinase inhibitor, KT5823 blocked the suppressive
effect of NO on Rho A activity, suggesting that cGMP/cGMP-
dependent kinase pathway plays an important role in this
action. It was recently reported that cGMP-dependent kinase
directly phosphorylates and inactivates Rho A.29 The same
mechanism may be involved in the inhibition of Rho A activity
by NO in human SMCs.
This study demonstrated that the Rho A pathway is
a target of NO to exert its antimigratory effects in human
vascular SMCs. This therefore provides a new therapeutic
approach for the treatment of human vascular disease
associated with increased migration of SMCs, such as
restenosis and venous bypass graft disease.
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Cyclophilin A differentially activates monocytes and endothelial
cells Role of purity, activity, and endotoxin contamination
in commercial preparations
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bstract
ackground: Cyclophilin A (CyPA) is a cytoplasmic protein secreted under inflammatory conditions. Extracellular CyPA is detected in
therosclerotic plaques and has been observed to activate endothelial cells as well as monocytes.
ethods and results: Commercially available recombinant CyPA-induced expression of tissue factor (TF) and vascular cell adhesion
olecule-1 (VCAM-1) in human aortic endothelial cells (HAEC). However, CyPA from commercial sources contained lipopolysac-
haride at concentrations up to 18.9 ng/ml; moreover, it exhibited low purity as determined by protein spectrum analysis and low
ctivity as assessed by peptidyl prolyl cis–trans isomerase (PPIase) assay. An in-house preparation of pure, active, and uncontaminated
yPA failed to induce endothelial TF or VCAM-1 expression; moreover, it was not chemotactic for HAEC. In contrast, such CyPA
xhibited potent chemotactic activity on monocytic THP-1 cells, with a maximal effect on migration occurring at a concentration of
.5 × 10−9 mol/l. Pretreatment of CyPA with cyclosporine A prevented its effect on THP-1 cell migration; similarly, PPIase-deficient mutant
yPA protein did not induce migration of these cells. In-house prepared CyPA induced the release of Il-6, but not TNF-, from THP-1
ells.
onclusions: Commercially available CyPA exhibits low purity and activity and may be contaminated by endotoxin. Pure, active, and
ncontaminated CyPA does not induce endothelial TF or VCAM-1 expression; instead, it acts as a potent monocyte chemoattractant and
nduces monocyte Il-6 release, implying a role for extracellular CyPA in the pathogenesis of atherosclerosis via activation of monocytes rather
han endothelial cells.
2007 Elsevier Ireland Ltd. All rights reserved.
ndotheeywords: Cyclophilin A; Tissue factor; Lipopolysaccharide; Monocytes; E. Introduction
Cyclophilin A (CyPA) belongs to the immunophilin fam-
ly and is an abundantly expressed cytosolic protein found in
∗ Corresponding author at: Cardiovascular Research, Institute of Phys-
ology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich,
witzerland. Tel.: +41 44 6356469; fax: +41 44 6356827.
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oi:10.1016/j.atherosclerosis.2007.08.025lial cells
ost prokaryotes and eukaryotes [1,2]. Intracellular CyPA
ossesses multiple functions, among which peptidyl prolyl
is-trans isomerase (PPIase-) activity is considered to be
mportant for protein folding [3,4]. Furthermore, CyPA is the
ytoplasmatic host cell receptor for the immunosuppressive
rug cyclosporine A (CsA), which is commonly employed
o prevent organ rejection after transplantation [5,6]. CsA
nhibits PPIase activity of CyPA; this effect, however, is
hought to occur independent of its immunosuppressive
ction.
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Although CyPA was initially assumed to exist only intra-
ellularly, numerous observations demonstrate that it can also
e released into the extracellular space [7]. Indeed, CyPA
s secreted from monocytes [7], endothelial cells [8], and
ascular smooth muscle cells [9] in response to a variety
f inflammatory stimuli; furthermore, extracellular CyPA
s detected in the inflammatory microenvironment of the
therosclerotic vessel wall [10]. Extracellular CyPA has been
eported to trigger endothelial cell activation and to promote
ndothelial cell migration in response to inflammatory stimuli
8,10], hinting at a possible role for CyPA as an inflamma-
ory mediator. In particular, CyPA released in response to
ncreased levels of reactive oxygen species was described
o activate the endothelium by inducing the expression of
CAM-1 and E-selectin, thereby favoring the development
f atherosclerotic lesions [10].
In this study, we attempted to elucidate the mechanisms
y which extracellular CyPA triggers endothelial activation.
. Materials and methods
.1. Cell culture
Human aortic endothelial cells (HAEC, Clonetics #CC-
535) were cultured as described [11]. Cells were grown
n EGM-2 (Clonetics #CC-4176) medium supplemented
ith 10% fetal calf serum (FCS, Biowhittaker #14-471F).
ubconfluent cells were rendered quiescent for 24 h in
BM-2 (Clonetics #CC-3156) with 0.5% FCS before stim-
lation with CyPA (BIOMOL #SE-105, Sigma #C3805,
albiochem #239777) or TNF- (R&D #210-TA). The
onocytic cell line THP-1 was grown in RPMI 1640
edium (GIBCO #21875-034) supplemented with 2 mM
-glutamine (GIBCO #25030-024), 100 U/ml Penicillin,
00g/ml Streptomycin (GIBCO #15140-122) and 10%
CS (GIBCO #10270-106). To assess cytotoxicity, a colori-
etric assay for detection of lactate dehydrogenase was used
ccording to the manufacturer’s recommendations (Roche
11644793001) as described [12]. To determine endotoxin
oncentration, a limulus amoebocyte lysate assay with a
etection limit of 0.125 U/ml was used according to the
anufacturer’s recommendations (Cambrex #N283-125) as
escribed [13].
.2. CyPA protein puriﬁcation
Recombinant CyPA wild-type and CyPA R55A variant (in
hich arginine at position 55 – located in the active site – is
ubstituted by alanine) proteins were over-expressed in the
. coli M15 strain and induced with 1 mM isopropyl-beta-
-thiogalactopyranoside for 5 h at 37 ◦C. Cells were lysed in
0 mM tricine buffer (pH 8.0), and lysates were purified by
n anion exchange column (Fractogel EMD DEAE-650(M)).
he flow through was collected and applied to an affinity
olumn (Fractogel TSK AF-Blue). CyPA was eluted by a gra-
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ient of 0–3 M KCl in 20 mM tricine buffer (pH 8.0). Eluted
ractions were collected and dialyzed twice against 10 mM
EPES (pH 7.0). CyPA was further purified by a Fractogel
O-3 exchange column, and the protein was eluted with a
–1 M gradient of NaCl. Collected fractions were examined
or purity by SDS-PAGE, HPLC, and the calculated extinc-
ion coefficient in the protein spectrum; the preparation was
roven to be 94% pure.
.3. Peptidyl prolyl cis–trans isomerase activity assay
PPIase activity was determined using the peptide
-succinyl-Ala-Ala-Pro-Phe-4-nitroanilide (L-1400;
ACHEM) in a protease-coupled assay [3]. The test peptide
xists in both cis (15%) and trans (85%) form under normal
onditions. Chymotrypsin cleaves the Phe-pNA bond, but
nly when the Ala-Pro bond is in the trans conformation,
eaving the cis form in uncleaved in the reaction mixture.
yPA catalyzes the cis to trans interconversion of the
emaining part of the substrate that can be followed by
onitoring the progress curves of proteolysis. Reaction
rogress exhibits biphasic kinetics and can be monitored at
90 nm due to the production of 4-nitroaniline. Absorbance
t 390 nm was determined spectrophotometrically dur-
ng 240 s. All PPIase experiments were performed with
n-house prepared CyPA at concentrations in the low
anomolar range (0.5–2.0 nM) and were compared to
ommercial CyPA protein preparations. The enzymatic
ctivity of CyPA is indicated by its catalytic efficiency
kcat/Km).
.4. Western blot analysis
Protein expression was determined by Western blot analy-
is as described [14]. Antibodies against human tissue factor
TF, American Diagnostica #4503) and vascular cell adhesion
olecule-1 (VCAM-1, R&D #BBA19) were used at 1:2,000
nd 1:2,500 dilution, respectively. Blots were normalized to
-tubulin expression (1:40,000, Sigma #T5168).
.5. Chemotaxis assay
Chemotactic activity was assessed in a 48-well modi-
ed Boyden chamber (Neuroprobe, Gaithersburg, Maryland,
SA) containing two compartments separated by a polyvinyl
yrrolidone free (PVPF) polycarbonate filter with a pore-
ize of 5m as described [15]. Chemoattractants (CyPA or
onocyte chemoattractant protein-1 (MCP-1, R&D #279-
C)) were diluted in control medium (EBM-2 + 0.1% BSA
or endothelial cells, RPMI + 0.1% BSA for THP-1 cells)
nd loaded into the lower chamber. 100 ng/ml MCP-1 and
0% FCS were used as positive controls for migration of
onocytes and endothelial cells, respectively. Cyclosporine
(CsA, 10−6 mol/l) and CyPA (R55A) mutant protein were
pplied to analyze the role of PPIase activity in CyPA-induced
igration.
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Fig. 1. Purity and activity of in-house prepared versus commercial CyPA.
In-house prepared recombinant Cyclophilin A (CyPA) exhibits high purity
according to its protein spectrum (A, red line), and high peptidyl prolyl
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.6. ELISA
THP-1 cells were seeded in 12 well plates at a density
f 1 × 10−6 ml in starvation medium (0.5% FBS-RPMI) and
eft for 20 h. Cells were then stimulated with different con-
entrations of CypA and appropriate controls for additional
4 h. Supernatants were collected and 100l was used both
or TNF- (Bender MedSystems, #BMS223/3, Burlingame,
A) and IL-6 ELISA (R&D systems, Quantikine, #D6050,
bingdon, UK) according to the manufacturer’s instructions.
.7. Statistical analysis
Data are presented as mean ± S.E.M. Unpaired student
-test was applied to compare two groups, ANOVA with Bon-
erroni’s correction was used for three or more groups. A
alue of p≤ 0.05 was considered significant.
. Results
.1. Purity and activity of recombinant CyPA
The purity of an in-house preparation of recombi-
ant CyPA, as assessed by sodium dodecyl sulfate–
olyacrylamide gel electrophoresis and Coomassie blue
taining, was > 95%. The E280/E260 absorption ratio of 1.35
f this preparation indeed indicates only minor amounts
f non-proteinaceous impurities (Fig. 1A). This preparation
isplayed high PPIase activity reaching a specificity con-
tant (kcat/Km) of 9.6 × 106 M−1 s−1 (Fig. 1B); moreover, the
reparation contained no LPS (Fig. 2B).
Compared to the in-house prepared CyPA, all commercial
reparations displayed high amounts of non-proteinaceous
mpurities as judged by theE280/E260 absorption ratios, which
ere found to be 0.95 and 0.72 for BIOMOL lot #T5002 and
ot #T5068, respectively, and 0.93 for the lot of Calbiochem.
oreover, the spectra revealed a high variability between
ifferent lots. Sample turbidity as indicated by an absorbance
ignal at wavelength above 310 nm suggested the existence
f aggregated proteins in lot #T5002 and lot #T5068 from
iomol. Purity was highest in the lot from Sigma with an
280/E260 absorption ratio of 1.21 (Fig. 1A).
The lots from BIOMOL and Calbiochem did not exhibit
ny measurable PPIase activity, while the Sigma preparation
isplayed low activity, reaching a maximal catalytic effi-
iency (kcat/Km) of 9.1 × 105 M−1 s−1 (Fig. 1B). Compared
o the Sigma lot, the in-house prepared CyPA still had a 12.5
imes higher catalytic efficiency (Fig. 1B).
.2. Commercial CyPA induces endothelial expression
f TF and VCAM-1 due to endotoxin contaminationHAEC were stimulated with increasing concentrations
10−8–10−6 mol/l) of recombinant CyPA (BIOMOL; lot
T4437) for 5 h, which resulted in a concentration-dependent
d
f
w
ois–trans isomerase activity in the peptide substrate assay (B, red line).
ommercial recombinant CyPA preparations from different sources exhibit
ow purity (A) and very low PPIase activity as compared to in-house prepared
yPA (B).
nduction of TF and VCAM-1 protein expression. Maximal
nduction of TF and VCAM-1 occurred at 10−6 mol/l and
eached 7-fold and 4-fold, respectively, as compared to basal
xpression (Fig. 2A). To control for endotoxin contaminating
he recombinant protein, the LPS level in the CyPA prepa-
ation was quantified by a limulus amoebocyte lysate assay.
PS concentration was over 15,000 U/ml (18.87 ng/ml) in
IOMOL CyPA (lot #T4437), while other lots from the same
s well as from different sources contained lower endotoxin
oncentrations (Fig. 2B). CyPA preparations without signifi-
ant LPS contamination (e.g. BIOMOL CyPA lot #T5002 or
ot #T5064) did not exert any effect on endothelial expres-
ion of TF or VCAM-1 (data not shown). On the other
and, purified LPS induced endothelial expression of TF and
CAM-1 in a concentration-dependent manner from 10−8 to
0−6 mol/l as expected [13] (Fig. 2C). Notably, stimulation
ith 30 ng/ml LPS (i.e. approximately the LPS concentration
etected in BIOMOL CyPA lot #T4437) resulted in a 6-
old and 10-fold induction of TF and VCAM-1, respectively,
hich was comparable to the TF and VCAM-1 induction
bserved with BIOMOL CyPA lot #T4437. CyPA was not
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Fig. 2. Commercial CyPA induces endothelial TF and VCAM-1 expression. (A) Commercial Cyclophilin A induces expression of tissue factor (TF) and
vascular cell adhesion molecule-1 (VCAM-1) in HAEC in a concentration-dependent manner. Values are provided as fold increase over unstimulated control.
*p < 0.001. (B) Endotoxin levels of commercial recombinant CyPA preparations as measured by the limulus amoebocyte lysate assay. (C) LPS significantly
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-tubulin (T) expression.
ytotoxic as determined by an LDH release assay (data not
hown).
.3. Pure and active CyPA does not activate endothelial
ells
In contrast to LPS-contaminated, commercial CyPA
Fig. 2), pure and active, in-house prepared CyPA did not
nduce endothelial TF or VCAM-1 expression at concen-
rations as high as 10−6 mol/l (Fig. 3A and B). Moreover,
uch CyPA did not exhibit any chemotactic activity on
f
pntative of at least three different experiments; all blots are normalized to
ndothelial cells (Fig. 3C). In all experiments, endothelial
ells responded properly towards the respective positive con-
rols included in the experiments (5 ng/ml TNF- for TF
r VCAM-1 induction and 10% FCS for migration, respec-
ively).
.4. Pure and active CyPA is a strong chemoattractant
or THP-1 cells
Similar to endothelial cells, pure and active, in-house
repared CyPA failed to induce TF expression in THP-
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Fig. 3. Effects of pure and active CyPA on endothelial activation. (A)
Pure and active Cyclophilin A (CyPA) does not induce endothelial tissue
factor (TF) protein expression at concentrations from 10−8 to 10−6 mol/l
(p = n.s.). (B) Pure and active CyPA does not induce endothelial vascular cell
adhesion molecule-1 (VCAM-1) expression at concentrations from 10−8 to
10−6 mol/l (p = n.s.). All blots are representative of at least three different
experiments; all blots are normalized to -tubulin (T) expression. (C) Pure
and active CyPA does not exhibit any chemotactic activity on endothelial
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cells at concentrations up to 10−6 mol/l (n = 3, p = n.s.,
ata not shown). In contrast to endothelial cells, however,
he in-house preparation of CyPA-induced migration of
HP-1 cells in a Boyden chamber assay. The response to
ncreasing concentrations of CyPA (10, 100, and 1000 ng/ml)
esulted in a bell-shaped curve with the highest number of
ells migrating in response to 100 ng/ml (5.5 × 10−9 mol/l,
ig. 4). This concentration of CyPA exhibited 60% of
he chemotactic activity exerted by 100 ng/ml MCP-1, a
w
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nown potent chemoattractant for monocytes (Fig. 4A).
o control for chemokinesis, CyPA was loaded into both
he upper and the lower chamber; migration of THP-
cells could not be detected under these conditions
Fig. 5B).
.5. PPIase activity is required for CyPA-induced
igration of THP-1 cells
The active site (hydrophobic pocket) of the CyPA
olecule exhibits PPIase activity, which is essential for many
f its actions. The role of PPIase activity for induction of
HP-1 cell migration was first assessed using CsA, which
inds to the catalytic site of CyPA inhibiting its PPIase activ-
ty [6]. Pretreatment of CyPA with CsA for 10 min abrogated
he effect of CyPA on chemotaxis of monocytes (Fig. 5A).
sA alone did not affect THP-1 cell migration, and addition
f CsA to MCP-1 had no effect on MCP-1 induced THP-
cell migration, ruling out a non-specific effect of CsA on
HP-1 cell chemotaxis (Fig. 5A). The involvement of PPIase
ctivity in CyPA-induced THP-1 cell migration was con-
rmed by a PPIase-deficient CyPA mutant (R55A), which
xhibits only 1% of the PPIase activity of wild-type CyPA;
his mutant protein failed to induce migration of THP-1 cells
Fig. 5B).
.6. Pure and active CyPA induces Il-6-, but not TNF-α
elease from THP-1 cells
In order to further analyze the effect of pure and active
yPA as a potential pro-inflammatory mediator, we examined
ts effect on cytokine release from THP-1 cells. Interest-
ngly, CyPA did not lead to TNF- release (Fig. 6A), but
ignificantly induced Il-6 release (Fig. 6B).
. Discussion
This study demonstrates that pure and active CyPA is a
otent chemoattractant for monocytes; in contrast, CyPA fails
o activate endothelial cells as assessed by induction of TF and
CAM-1 expression as well as by endothelial cell migration.
Pure and active CyPA did not induce endothelial TF and
CAM-1 expression; an effect on these proteins was only
bserved when the samples were contaminated by signifi-
ant concentrations of LPS. These data stand in contrast to
arlier studies demonstrating that CyPA induces endothelial
CAM-1 expression and MAP kinase activation [10]. In this
articular study, heat-inactivation (i.e. boiling for 20 min)
f CyPA was applied as the only method to exclude LPS
ontamination. Heat-inactivation of protein preparations has
een widely used in the past for ruling out contamination
ith endotoxin, since LPS is relatively heat-resistant; how-
ver, more recent studies have demonstrated that LPS turns
ut to be quite heat-sensitive, especially when compared to
ery heat-resistant inducers of TF, such as histamine [13,16].
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Fig. 4. Effects of pure and active CyPA on monocyte chemotaxis. (A) Pure and active Cyclophilin A (CyPA) is chemotactic for monocytic THP-1 cells
(n = 4; *p < 0.01; **p < 0.001). Migration is expressed as percent of control conditions (RPMI + 0.1% BSA). (B) THP-1 cells migrate in response to different
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moncentrations of pure and active CyPA (10–1000 ng/ml) with a maximal eff
ells are stained with DAPI and counted under a fluorescent microscope at 1
ence, heat-sensitivity of a protein preparation does not seem
ufficient to rule out that a biological effect results from
ndotoxin contamination. We therefore measured LPS con-
entrations in the present study and detected a significant
oncentration of LPS (18.87 ng/ml) in the only commercial
yPA preparation inducing TF and VCAM-1 expression;
otably, stimulation with a similar concentration of puri-
ed endotoxin resulted in a comparable induction of TF
nd VCAM expression. In contrast, pure and active, in-
ouse prepared CyPA did not affect endothelial TF and
CAM expression; moreover, commercial CyPA prepara-
ions lacking significant LPS contamination did not induce
xpression of TF and VCAM-1 either. Taken together, these
esults indicate that CyPA does not induce endothelial TF or
CAM-1 expression and that such effects occur solely due
o endotoxin contamination of the respective protein prepa-
ation.
Potential LPS contamination, however, does not seem
o be the only pitfall with commercially available CyPA
reparations. Indeed, commercially available CyPA exhibits
oth low purity and activity as compared to in-house pre-
ared CyPA. PPIase activity was used to determine the
ioactivity of different CyPA preparations, as this is con-
idered to be the most sensitive property for monitoring
he bioactive, native state of CyPA [3]. Compared to in-
ouse prepared CyPA, all commercial preparations displayed
oor activity; the lots from BIOMOL and Calbiochem were
irtually inactive, while the Sigma preparation exhibited
[
p
e
prring at 100 ng/ml. MCP-1 (100 ng/ml) is used as positive control. Migrated
nification.
ow activity. Although several different lots of the com-
ercial providers were repeatedly tested with the same
esults, it cannot be excluded that other preparations from
he same manufacturers display higher purity and/or activ-
ty. Great care was taken regarding the proper handling
f all the preparations. Although handling mistakes lead-
ng to contamination or loss of activity can never be ruled
ut completely, such mistakes indeed seem rather unlikely,
ince all the commercial preparations exhibited low purity
nd activity even without storage, while in-house prepared
yPA exhibited PPIase activity even after 1 year of stor-
ge.
Although the CyPA sequence lacks a secretion signal,
umerous observations have demonstrated that it may be
ecreted into the extracellular space in response to inflamma-
ory stimuli [7–9]. Recent studies indeed revealed high levels
f extracellular CyPA in atherosclerotic plaques of ApoE
nockout mice [10]; furthermore, CyPA has been demon-
trated in the synovial fluid of rheumathoid arthritis patients
17]. Hence, there is increasing evidence for a role of CyPA
n inflammatory diseases including atherosclerosis. Migra-
ion of leucocytes into the arterial wall represents a key event
n the development of atherosclerotic plaques and is deter-
ined by the local concentrations of chemotactic mediators
18]. We demonstrate that pure and active, in-house pre-
ared CyPA exhibits potent chemotactic effects on monocytes
qualing 60% of that induced by MCP-1. The chemotactic
roperties of CyPA appear to critically depend on its PPIase
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Fig. 5. Role of CyPA peptidyl prolyl cis-trans isomerase (PPIase) activ-
ity in monocyte migration. (A) Pretreatment of Cyclophilin A (CyPA) with
cyclosporine A (CsA) blocks migration of THP-1 cells (**p= 0.01 as com-
pared to control); in contrast, addition of CsA has no effect on chemokinesis
(p = n.s. as compared to control) and on MCP-1 induced migration (p = n.s.
as compared to MCP-1 alone). Migration is expressed as percent of control
conditions (0.1% BSA + RPMI). Bars are representative of four different
experiments. (B) R55A, a PPIase-deficient CyPA mutant, does not exert any
chemotactic activity on THP-1 cells (n = 6; **p < 0.01 as compared to active
CyPA). To control for chemokinesis, pure and active CyPA was loaded into
b
o
a
a
P
o
c
p
c
w
c
s
m
I
C
u
r
o
o
l
s
p
p
m
i
u
W
m
m
i
v
t
H
d
p
p
a
w
O
t
i
t
a
s
r
u
e
a
a
t
i
c
d
d
s
a
i
a
e
n
further studies are necessary to investigate whether pre-oth the upper and the lower chamber resulting in no measurable migration
f THP-1 cells (n = 6, p = n.s. as compared to control).
ctivity, as blocking of this activity by CsA as well as by
s by application of a point mutated CyPA variant that lacks
PIase activity failed to induce monocyte migration. These
bservations suggest that CyPA may play a role in mono-
yte recruitment and thereby contribute to atherosclerotic
laque formation. The reason why CyPA-induced mono-
yte migration displays a biphasic concentration-dependency
ith the effect being most pronounced at intermediate con-
entrations (100 ng/ml) remains to be elucidated in further
tudies.
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In order to further examine the role of CyPA as an inflam-
atory mediator in atherosclerosis, the release of TNF- and
l-6 by THP1 cells after stimulation with pure and active
yclophilin A was examined. Interestingly, a marked stim-
lation of Il-6 release was observed, while that of TNF-
emained unaffected. The effect on Il-6 is consistent with
ther studies in which Il-6 release by secreted PPIases was
bserved in macrophages [19]. Hence, in addition to stimu-
ating THP-1 cell chemotaxis, CyPA induces the release of
pecific cytokines without leading to a generalized release of
ro-inflammatory mediators.
In contrast to monocytes, even high concentrations of
ure and active CyPA had no effect on endothelial cell
igration, which stands in contrast to an earlier study report-
ng that commercial CyPA (BIOMOL) enhanced human
mbilical vein endothelial cell (HUVEC) migration [8].
hile differences in cell origin or cell culture protocols
ay in principle account for this discrepancy, no assess-
ent of purity, activity, or LPS contamination was reported
n that study; therefore, it is difficult to confer our obser-
ations on that study, both regarding the mediator and
he mechanism responsible for the action of CyPA on
UVEC.
CsA is routinely used to prevent organ rejection after car-
iac transplantation. Blocking of CyPA activity with CsA
revented CyPA-induced monocyte migration implying a
otential beneficial effect of CsA on the development of
therosclerosis. Indeed, treatment of cholesterol-fed rabbits
ith CsA reduces early atherosclerotic lesion formation [20].
ther studies, however, have demonstrated that CsA adminis-
ration is associated with endothelial dysfunction [21] and an
ncreased risk for the development of atherosclerosis [22];
hese effects seem to result from a reduced nitric oxide
vailability and a concomitant increase in reactive oxygen
pecies. Overall, the effect of CsA on transplant atheroscle-
osis remains controversial; while some studies associate the
se of CsA with an increased risk for coronary artery dis-
ase [23], others do not see such an effect or even observe
reduction in the occurrence of coronary artery disease
fter heart transplantation [24,25]. Thus, it is conceivable
hat CsA may impair CyPA-induced monocyte migration
n such patients, while this potentially protective effect is
ounterbalanced by concomitant less beneficial actions of the
rug.
In summary, pure and active, in-house prepared CyPA
oes neither induce endothelial TF and VCAM-1 expres-
ion nor enhance endothelial cell migration, but instead
cts as a potent chemoattractant for monocytes imply-
ng a role for extracellular CyPA in the pathogenesis of
therosclerosis. In contrast, commercially available CyPA
xhibits low purity and activity and may also display sig-
ificant endotoxin contamination. In light of these findings,iously reported effects of CyPA are truly attributable to
yPA or rather occur because of endotoxin contamina-
ion.
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6. Discussion and Outlook 
 
In this study, we focused on pathogenetic aspects of bypass graft disease. For 
the first time we showed that smooth muscle cells from bypass vessels (IMA and SV) 
exhibit a differential gene expression profile related to the blood coagulation system 
and different chemotactic properties to several stimuli. 
Our findings demonstrate that, among all the genes of the coagulation system, 
only TF and tPA are differentially regulated in IMA and SV. Tissue factor, the key 
protein in blood coagulation was expressed at a lower level in IMA, whereas tPA, a 
major regulator of fibrinolysis, was expressed at a higher level. Consistently, 
conditioned media from IMA cells delayed clotting time of human plasma. Moreover, 
a weaker response to TF/FVIIa mediated migration was observed as compared to SV-
SMC. These differences at the molecular and cellular level represent intrinsic 
functional differences between IMA and SV SMC.  
 PDGF-BB elicited migratory responses only in SMC, but not in endothelial 
cells isolated from human bypass vessels (IMA and SV). PDGF-BB induced a weaker 
proliferation, migration, and stress fiber formation in SMC from IMA, while this effect 
was pronounced in SV. Stress fiber formation in these cells was regulated by the RhoA 
pathway. This finding was consistent with the lower PDGFR-β expression in IMA 
SMC. Another study on the regulation of the Rho/ROCK pathway showed that low 
levels of nitric oxide production in these cells inhibited the PDGF mediated migration 
in SV. We used DETANO as a pharmacological source of NO because this molecule 
exhibits very slow and prolonged first order release kinetics of the free radical, which 
is most suitable for cell culture experiments. Over expression of eNOS provided 
another approach for the inhibition of smooth muscle cells. Using an adenoviral 
vector, we successfully transduced eNOS into human vascular SMC as demonstrated 
by western blot. PDGF mediated migration response in eNOS adenovirus transfected 
SV-SMC was blocked by the eNOS inhibitor L-NAME, demonstrating that NO indeed 
is involved. These specific functional differences of SMC may play a distinct role in 
the vascular remodeling process. Although performed in vitro, these experiments with 
human VSMC demonstrated an anti-thrombogenic gene expression profile, lower 
migration rates, and lower stress fiber formation from IMA, offering explanation for 
the protection of IMA from thrombosis, atherogenesis, and bypass graft disease.  
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In summary, this thesis reveals intrinsic differences of human SMC from IMA 
and SV related to both blood coagulation and vascular remodeling. SV-SMC exhibited 
higher TF and lower t-PA protein and activity as compared to IMA-SMC. Supernatant 
from SV-SMC decreased the clotting time of human plasma as compared to IMA-
SMC, underlining the prothrombotic environment in SV-SMCs. SV-SMC exhibited 
increased migration towards the TF/FVII complex and PDGF-BB as compared to 
IMA-SMC. The higher migration levels in response to PDGF-BB were paralleled by 
higher activity of the small GTPase, RhoA in SV-SMC as compared to MA-SMC. 
Nitric oxide mediated inhibition of RhoA activity by pharmacological as well as gene 
transfer methods abrogated migration of SV-SMCs. 
These findings may offer a possible explanation for the differential patency 
rates of IMA and SV grafts observed in patients with CABG. Although performed in 
human cells, lack of a proper mouse model to study the disease aspects limits the 
extrapolation of current results to the in vivo situation. 
  
  
 
 
The relative differences in thrombosis (TF, tPA & TFPI) and inflammation related protein expression (PDGF 
& Rho A) in vascular smooth muscle cells from internal mammary artery (IMA) & saphenous vein (SV). 
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